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Summary 
Mastocytosis is a rare disease characterized by neoplastic accumulation of mast cells in 
various organs, particularly in skin and bone marrow. Sporadic mastocytosis is usually 
caused by somatic point mutations of the receptor tyrosine kinase KIT that occur in exon 17, 
codon 816, and activates KIT by affecting the intracellular enzymatic site of the molecule. 
Homeostasis of so altered mast cells is influenced on different levels. These cells show an 
elevated rate of proliferation and changes in cellular apoptosis. In this thesis the expression 
of the inhibitor of apoptosis protein (IAP) Survivin in neoplastic mast cells and its importance 
as a diagnostic marker or therapeutic target has been evaluated. For this purpose the 
Survivin content of normal and neoplastic mast cells was analyzed. Furthermore Survivin 
expression in mast cells of bone marrow samples from patients with mastocytosis and 
healthy donors was compared. The expression of Survivin protein in the neoplastic human 
mast cell line HMC-1 was downregulated by siRNA and apoptosis was subsequently induced 
with tyrosine kinase inhibitors or the death receptor ligand TRAIL. It is known from other 
hematopoietic neoplasia that Smac mimetics, inhibitors of the IAPs XIAP, cIAP1 and cIAP2, 
are potent therapeutics able to amplify the effect of classical cytotoxic therapies. Here the 
Smac mimetic LCL161 was used in combination with the tyrosine kinase inhibitor PKC412 
and TRAIL to inhibit growth of the neoplastic mast cell line HMC-1. 
The expression of the IAP Survivin is enhanced in neoplastic altered mast cells and can be 
detected in significantly higher amounts in mast cell infiltrates of the bone marrow from 
patients with mastocytosis compared to healthy donors underlining its value as a diagnostic 
marker. Downregulation of Survivin protein as well as the use of the Smac mimetic LCL161 
inhibited the growth of the neoplastic mast cell line HMC-1 synergistically with tyrosine 
kinase inhibitors and the death receptor ligand TRAIL. These results emphasize the 
relevance of cellular regulation of apoptosis as a future target for the therapy of 
mastocytosis. 
 
 
 
 
 
 
 
 
 
 
 
 Zusammenfassung 
 
Mastozytose ist eine seltene Erkrankung die durch eine neoplastische Akkumulation von 
Mastzellen in unterschiedlichen Organen, insbesondere der Haut und dem Knochenmark 
charakterisiert ist. Auslöser für die Mastozytose sind oftmals aktivierende somatische 
Punktmutationen in Exon 17, Codon 816 des Gens der Rezeptortyrosinkinase KIT, welche 
die intrazelluläre enzymatische Domäne des Rezeptors beeinflussen. Die Homöostase 
derartig veränderte Mastzellen ist auf mehreren Ebenen gestört. So konnte nicht nur eine 
erhöhte Proliferationsrate, sondern auch ein verändertes Apoptoseverhalten nachgewiesen 
werden. In dieser Arbeit wurde die Expression des inhibitor of apoptosis Proteins (IAP) 
Survivin in neoplastisch veränderten Mastzellen und seine Bedeutung als diagnostischer 
Marker sowie als therapeutisches Target untersucht. Hierzu wurden gesunde und 
neoplastisch veränderte Mastzellen auf ihren Survivingehalt hin überprüft sowie die 
Survivinexpression der Mastzellen in Knochenmarksstanzen von Mastozytosepatienten mit 
denen gesunder Probanden verglichen. Des weiteren wurde die Expression von Survivin in 
der neoplastischen Mastzelllinie HMC-1 mit Hilfe von siRNA herunterreguliert und Apoptose 
mithilfe von Tyrosikinaseinhibitoren und dem Todesrezeptorliganden TRAIL induziert. Aus 
anderen hämatopoetischen Neoplasien ist bekannt, dass sogenannte Smac mimetics, 
Moleküle, die die IAPs XIAP, cIAP1 und cIAP2 binden und inaktivieren können, potente 
Therapeutika sind, die in der Lage sind, die Wirkung klassischer zytotoxischer Therapien zu 
verstärken. Hier wurde das Smac mimetic LCL161 in Kombination mit dem 
Tyrosinkinaseinhibitoren PKC412 sowie TRAIL verwendet, um das Wachstum von HMC-1 
Zellen zu hemmen. 
Das IAP Survivin wird verstärkt in neoplastisch veränderten Mastzellen exprimiert und ist in 
Mastzellinfiltraten im Knochenmark von Mastozytosepatienten in signifikant höheren Mengen 
nachzuweisen als in denen gesunder Probanden, was den Wert des Proteins als 
diagnostischen Marker herausstellt. Die Herunterregulierung des Survivin Proteins, ebenso 
wie der Einsatz des Smac mimetic LCL161 hemmte das Wachstum der neoplastischen 
Mastzelllinie HMC-1 im Synergismus mit Tyrosinkinaseinhibitoren oder dem Todesliganden 
TRAIL. Dies unterstreicht die Bedeutung der zellulären Apoptoseregulation als zukünftiges 
Ziel der medikamentösen Therapie der Mastozytose. 
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1 Introduction 
1.1 Mast cells 
Mast cells were first described by Paul Ehrlich in 1878 as cells containing granules which can 
be stained red with aniline blue (Metachromasy) (Ehrlich 1878). He speculated that the cells 
were “fattened” (german: “gemästet”) by phagocytosis and so termed them mast cells. Today 
it is known that these granules contain preformed mediators that can be released after 
stimulation (Bradding 1996; Metcalfe, Baram et al. 1997) and that mast cells are important 
effector cells of the immune system. They can be found in tissue forming the inner and outer 
barrier of an organism like the skin or the mucosa of the lung and the gut. During a type-I 
allergic reaction, immunoglobine E (IgE) produced by B lymphocytes binds to the membrane 
bound IgE receptor I (FcεRI) on the mast cell. When antigen is crosslinking the receptors, 
mainly preformed mediators from the cytoplasmic granules like histamine, heparin, lipid 
mediators or cytokines are released.  
1.1.1 Development of mast cells 
Mast cell progenitors (MCP) arise from CD34+ hematopoietic stem cells in the bone marrow. 
These MCP emigrate via the blood circuit into different tissues where they maturate under 
the influence of stem cell factor (SCF) produced by different cells (i.e. fibroblasts). SCF binds 
to the mast cell receptor tyrosine kinase c-KIT (CD117). Mast cells are the only 
hematopoietic cells showing a high c-KIT expression during all stages of their development. 
MCP stimulation by SCF leads to formation of granules and maturation of mast cells 
(Kirshenbaum, Goff et al. 1992; Valent, Spanblochl et al. 1992). While human mast cells 
mainly depend on SCF for maturation and proliferation in the murine system other 
substances like interleukins (IL-3, IL-4 and IL-9) and nerve growth factor (NGF) have been 
described as regulators (Matsuda, Kannan et al. 1991; Rennick, Hunte et al. 1995). Different 
subtypes of mature mast cells can be distinguished by their localization and their 
histochemical properties. Three mast cell subtypes can be classified in humans by the 
protease content in their granules. Mast cells only containing tryptase (MCT), tryptase and 
chymase (MCTC) or chymase and cathepsin G (MCC) can be distinguished (Metcalfe 2008). 
While mast cells of the MCT subtype can be found mainly in the lung, the mucosa of the gut 
and the nose, the MCTC subtype resides in the skin, tonsils and the submucosa of the gut. 
The microenvironment of the tissue in which mast cells reside determines their sensitivity 
towards activating stimuli independent of their subtype. While skin mast cells can be 
activated by poly-L-lysine, the neuropeptide substance P, compound 48/80 or morphine, lung 
mast cells are insensitive towards these stimuli (Lowman, Rees et al. 1988). 
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1.1.2 Mast cell functions 
Mast cell degranulation, the exocytotic release of preformed or de-novo synthesized 
mediators can be triggered by various stimuli. The pattern of released substances is 
determined by the subtype and localization of the mast cell and the type and intensity of the 
stimulus. Preformed mediators can be substances like mast cell proteases, peptidoglycans, 
tumor necrosis factor (TNFα), vascular endothelial growth factor (VEGF) and fibroblast 
growth factor 2 (FGF2) while interferons, leukotrienes, chemokines can be synthesized upon 
activation (Marshall 2004). Besides activation via crosslinking of the FcεRI mast cell 
degranulation can be triggered by activation of complement receptors (C3a, C5a), Fcγ 
receptors, toll-like receptors and chemokine receptors. At the end the combination of triggers 
and their intensity determines the pattern of synthesized and released mediators from the 
mast cell (Gilfillan and Tkaczyk 2006). The physiological role of mast cells is their function in 
the innate as well as the acquired immunity in the control of infections with bacteria and 
parasites. It has been shown that mast cell released TNFα can help to control bacterial 
infection in a model of murine peritonitis (Echtenacher, Mannel et al. 1996) and nematode 
infections in mice lead to accumulation of mucosal mast cells in the gut with release of mast 
cell protease 1 (Knight, Wright et al. 2000).Toll-like receptors on mast cells are capable of 
binding microbial particles leading to release of cytokines like TNF, IL-6 and IL-8 stimulation 
immigration of effectors cells into infected tissues (Marshall 2004). Finally they are possibly 
linked to allograft tolerance (Lu, Lind et al. 2006) and tumor invasion (Gounaris, Erdman et 
al. 2007). In the context of allergy mast cells react to otherwise harmless antigen by release 
of several preformed mediators which directly influence the surrounding tissue. During the 
immediate hypersensitivity reaction, the enzyme tryptase, chymase, cathepsine G and 
carboxypeptidase activate a rebuilding of the connective tissue matrix by metalloproteases. 
Histamine and heparin are released, increase vessel permeability and trigger smooth muscle 
contractions. These effects are amplified by release of lipid mediators like leukotrienes C4, 
D4 and E4. These lipid mediators are also responsible for intensified mucoid secretion and 
maintenance of inflammatory reactions. The late onset reaction again is initiated by 
preformed and newly synthesized mast cell mediators. By secreting cytokines like TNFα, 
leukotriene B4 or histamine endothelial cells are activated which upregulate expression of 
adhesion molecules like P-selectine, E-selectine and ICAM-1 on their surface. To these 
molecules leucocytes like neutrophils, monocytes and CD4+ T cells can bind and migrate 
into the tissue by transmigration (Koh, Dupuis et al. 1993; Robinson, Hamid et al. 1993; 
Montefort, Gratziou et al. 1994). 
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1.2 Mastocytosis 
The term Mastocytosis describes disorders caused by the pathogenic increase of mast cell 
numbers in different tissues. The consequences that arise from mast cell burden and 
accumulation of their associated mediators can be both locally and systemically. Local mast 
cell accumulation in organs like skin, gastrointestinal tract, bone marrow, spleen and lymph 
nodes can be associated with different hematologic disorders (Metcalfe 2008). In Cutaneous 
Mastocytosis (CM) mast cell infiltrates are restricted to the skin and variants of CM are 
defined by their clinical presentation. In addition in Systemic Mastocytosis (SM) one or more 
internal organs predominantly the bone marrow are infiltrated by mast cells (Valent, Horny et 
al. 2001) often associated with hematologic disorders. The pathological proliferation of mast 
cells in Mastocytosis and the release of their mediators can cause symptoms including 
pruritus, flushing, nausea, diarrhea and vascular instability and in systemic Mastocytosis 
severe symptoms like Osteoporosis and organ failure occur. The complex pattern of 
symptoms and their severity leads to a classification listed by the World Health Organization 
(WHO) and subsequent prognosis for each case of Mastocytosis (Horny, Sotlar et al. 2007): 
Variant – Term (Abbreviation) Subvariants 
Cutaneous Mastocytosis (CM) 
Urticaria Pigmentosa (UP) = 
Maculopapular CM (MPCM) 
Diffuse CM (DCM) 
Mastocytoma of Skin 
Indolent Systemic Mastocytosis 
(ISM) 
Smoldering SM (SSM) 
Isolated bone marrow Mastocytosis 
(BMM) 
Systemic Mastocytosis with an 
associated clonal hematologic non-
mast cell lineage disease             
(SM-AHNMD) 
Systemic Mastocytosis with Acute 
Myeloid Leukemia (SM-AML) 
Systemic Mastocytosis with 
Myelodysplastic Syndrome (SM-MDS) 
Systemic Mastocytosis with 
Myeloproliferative Disorder (SM-MPD) 
Systemic Mastocytosis with Chronic 
Myelomonocytic Leukemia             
(SM-CMML) 
Systemic Mastocytosis with Non-
Hodgkin’s Lymphoma (SM-NHL) 
Systemic Mastocytosis with 
Hypereosinophilic Syndrome         
(SM-HES) 
Aggressive Systemic Mastocytosis 
(ASM) 
Lymphadenopathic SM with 
eosinophilia 
Mast cell Leukemia (MCL) Aleukemic MCL 
Mast Cell Sarcoma (MCS)  
Extracutaneous Mastocytoma  
 
Table 1.1 WHO Classification of Mastocytosis 
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1.2.1 Clinical presentation 
 
Cutaneous Mastocytosis (CM) 
CM shows a wide variety of skin alterations (Rueff, Dugas-Breit et al. 2006). Even though all 
lesions in CM are due to an abnormal elevated mast cell number in the dermis the number 
and morphology of efflorescences varies (Longley, Duffy et al. 1995). The most common 
subvariant of CM presents as disseminated macular or maculopapular rash, and is 
(descriptively) termed urticaria pigmentosa (UP) (Wolff, Komar et al. 2001) (Hartmann and 
Henz 2002). Diffuse CM is less frequently diagnosed. The solitary localized mastocytoma (of 
the skin) is also rare, and has a benign clinical course. Thus, most mast cell tumors of the 
skin appear to be benign in most cases. 
 
Indolent systemic mastocytosis (ISM) 
The most common systemic variant of mastocytosis is the indolent systemic mastocytosis 
(ISM) wich involves the skin with limited increase of mast cell number in other organs, in 
most cases the bone marrow (Valent, Horny et al. 2001). With a common onset in adult age 
ISM shows a prolonged clinical course in almost all patients with survival times of two 
decades and more. Besides bone marrow infiltrates, more than 90% of patients show 
maculopapular cutaneous mastocytosis / urticaria pigmentosa.  Level of serum tryptase is 
raised in comparison to cutaneous mastocytosis with levels of 20 to 200 µg/l. A rare variant 
of ISM is the so called smoldering systemic mastocytosis (SSM) with pronounced mast cell 
infiltration (>30% in bone marrow histology), organomegaly and tryptase levels above 200 
µg/l. 
 
Systemic mastocytosis with an associated clonal hematologic non 
mast cell lineage disease (SM-AHNMD) 
A small subgroup of patients with systemic mastocytosis develops an additional clonal 
disease of hematologic non-mast cell lineage cells like the myelodysplastic / 
myeloproliferative syndrome or myeloid leukemia. Generally these are myeloid neoplasia 
while systematic lymphatic diseases like lymphoma or myeloma are extremely rare in these 
patients.  
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Aggressive systemic mastocytosis (ASM) 
In rare cases an ISM can develop into an aggressive systemic mastocytosis (ASM) with 
progressive infiltration of immature mast cells and subsequent organ destruction and failure 
(Valent 1996). ASM is much less common than ISM comprising only about 5% of all SM 
patients. Possible symptoms are cytoplenias, malapsorption, bone fractures and signs of 
hepatopathy with loss of liver function (Horny, Sotlar et al. 2007). A rare subvariant of ASM 
with prominent eosinophilia of blood and tissues and generalized lymphadenopathy (clinically 
mimicking malignant lymphoma) has been described as lymphadenopathic mastocytosis with 
eosinophilia (Hauswirth, Sperr et al. 2002). 
 
Mast cell leukemia (MCL) 
In patient with mast cell leukemia smear preparations of the bone marrow show more than 
20% mast cells (Horny and Valent 2001). In case of a typical mast cell leukemia numbers of 
circulating mast cell in the blood are generally above 10% while in cases of aleukemic mast 
cell leukemia the numbers are below 10%. Prognosis of MCL is poor, mostly with survival of 
less than two years. 
 
Mast cell sarcoma (MCS) 
Localized mast cell proliferations are also extremely rare and include both the 
extracutaneous mastocytoma (of the lung) and the “true” mast cell sarcoma. It is noteworthy 
that the mast cell sarcomas reported occurred in tissues not commonly involved by SM 
(larynx, colon, meningeal site). All cases showed rapid progression and generalization with 
the terminal phase resembling MC leukemia. (Horny, Sotlar et al. 2007). 
 
1.2.2 Pathogenesis 
The most important growth factor for human mast cells is the cytokine stem cell factor (SCF). 
SCF binds to the tyrosine kinase receptor KIT (CD117) encoded by the proto-oncogene KIT. 
By KIT activation SCF induces various cell functions in mast cells like proliferation, 
differentiation, mediator release, migration and survival (Tsai, Takeishi et al. 1991; Mekori, 
Oh et al. 1993). The majority of all adult patients with mastocytosis carry a somatic KIT 
mutation in exon 17 codon 816 with substitution of asparagine by valine (D816V) leading to 
an autonomous ligand independent activation of KIT (Nagata, Worobec et al. 1995) (Longley, 
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Tyrrell et al. 1996) (Longley, Metcalfe et al. 1999). In seldom cases substitutions by other 
amino acids in codon 816 i.e. D816Y, D816H and D816F (Feger, Ribadeau Dumas et al. 
2002) or mutations in neighboring codons (D820G) (Liegl, Kepten et al. 2008) have been 
described. In contrast to adult patient only a subgroup of children with mastocytosis carry 
activating KIT mutations (Sotlar, Escribano et al. 2003) (Yanagihori, Oyama et al. 2005). To 
some extent pediatric patients show untypical (i.e. D816F, D816Y, R816K) or silent non 
activating (D816D) mutations. Despite these findings revealing the molecular cause of 
mastocytosis many questions concerning its pathogenesis still remain unanswered. In 
particular factors besides the activating KITD816V mutation affecting the heterogeneity of 
mastocytosis and factors which are active in cases without activating KIT mutations i.e. in 
pediatric patients still have to be discovered. 
 
1.2.3 Therapy 
Despite growing scientific knowledge no curative therapy for the treatment of mastocytosis is 
available (Escribano, Akin et al. 2002; Brockow 2004). Currently applied treatments base on 
reduction or antagonism of mediator release and reduction of mast cell numbers (Longley, 
Duffy et al. 1995; Golkar and Bernhard 1997; Marone, Spadaro et al. 2001). Since 
mastocytosis is a rare disease and treatment is not always necessary clinical studies with 
large patient numbers are currently not available. Thus recommended therapies base on 
isolated cases or case series. 
In cases of cutaneous mastocytosis education of patients about diagnosis, prognosis and 
possible trigger factors and their avoidance is of capital importance (Allison and Schmidt 
1997; Golkar and Bernhard 1997; Brockow 2004). Medication in most cases is 
symptomatically and in accordance with the patient’s subjective condition. Commonly 
corticosteroids, antihistamines or a psoralen + UVA (PUVA) treatment have to be considered 
(Escribano, Akin et al. 2002; Worobec and Metcalfe 2002). In case of periodical condition i.e. 
weekly swelling of skin lesions or flushes, regular medication with H1 antihistamines should 
be prescribed. Gastrointestinal conditions can be treated by H2 antihistamines, cromoglycic 
acid, proton pump inhibitors and antacids. Systemic administered corticosteroids can be 
effective in patients with frequent anaphylactic reactions or severe systemic conditions like 
ascites, diarrhea or malapsorption (Metcalfe 1991). Calcium, vitamin D or bisphosphonate 
come into considerations in cases with osteopenia or osteoporosis (Laroche, Bret et al. 
2007). In patients with progressed categories of systemic mastocytosis especially aggressive 
mastocytosis or mast cell leukemia cytoreductive therapies have to be considered. Interferon 
alpha for example can reduce mast cell numbers in patients with aggressive systemic or 
smoldering systemic mastocytosis (Kluin-Nelemans, Jansen et al. 1992; Lippert and Henz 
Introduction 10 
1996; Worobec, Kirshenbaum et al. 1996; Hauswirth, Simonitsch-Klupp et al. 2004). 
Cladribin (2-chlorodeoxyadenosine, 2-CDA) according to first studies is reducing mast cell 
numbers in patients with aggressive mastocytosis (Tefferi, Li et al. 2001; Kluin-Nelemans, 
Oldhoff et al. 2003).  
 
1.2.4 Tyrosine kinase inhibitors 
During the last years the use of drugs targeting the tyrosine kinase (TK) KIT has been 
proposed and inhibitors have been developed. The TK inhibitor imatinib (= STI571) is of none 
or low effectiveness in patients with KITD816V mutation most common in patients with 
mastocytosis since the mutation is leading to a steric alteration in the receptor preventing 
imatinib from binding to the ATP binding domain of KIT (Ma, Zeng et al. 2002; Vendome, 
Letard et al. 2005). However in patients carrying uncommon KIT mutations in exons 9 or 10 
imatinib leads to a reduction in mast cell numbers, lowered tryptase levels and improvement 
of clinical symptoms (Akin, Fumo et al. 2004; Zhang, Smith et al. 2006). Novel multi kinase 
inhibitors like midostaurin (PKC412), nilotinib (AMN107) or dasatinib (BMS354825) have 
been developed and undergo clinical testing (Gotlib, Berube et al. 2005; von Bubnoff, 
Gorantla et al. 2005; Gleixner, Mayerhofer et al. 2006). Reportedly midostaurin has 
remarkable effects on neoplastic mast cells in vitro as well as to induce remission in a patient 
with MCL carrying the activating D816V KIT mutation (Gotlib, Berube et al. 2005).  
 
1.3 Targeting of the inhibitor of apoptosis protein (IAP) family and   
TRAIL death receptors in cancer 
 
1.3.1 Apoptosis 
The ability of multicellular organisms to control cell number is the prerequisite for many 
physiological processes. The targeted destruction of cells is executed by an active molecular 
suicide program so called programmed cell death. So acting as a counterpart to cell division, 
apoptosis enables the organism to regulate cell number and to specifically kill harmful cells. 
Therefore the programmed cell death is of central importance in developmental processes 
and tissue homeostasis. A dysregulation with reduced or excessive cell death may lead to 
severe illnesses like cancer, autoimmune diseases or neurological disorders like Alzheimer 
or Parkinson disease (Thompson 1995). 
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Described early under varying names in 1972 the programmed cell death was finally named 
apoptosis by Kerr et al describing an uniformly cell death characterized by defined 
morphological changes of dying cells throughout various cell types and tissues (Kerr, Wyllie 
et al. 1972). Early characteristics of apoptosis are shrinking of the cell, condensation of 
chromatin and bubble formation of the cell wall. Later  DNA is fragmented by endonucleases 
and the whole cell collapses. Cell debris is packed into apoptotic vesicles and taken up by 
phagocytotic cells. Since the cell membrane remains intact during the whole process no 
cellular content is released into the cells surrounding. Therefore the apoptotic cell death does 
not trigger inflammation in contrast to cells dying by necrosis. Necrosis is a type of cell death 
induced by mechanical stress or other environmental factors. Here the plasma membrane is 
disrupted and cell content is released. This can trigger an immune response and often is 
accompanied by inflammations which can harm surrounding tissues (Edinger and Thompson 
2004).  
 
1.3.2 The extrinsic pathway of apoptosis 
The extrinsic or receptor mediated pathway of apoptosis for is used for example in cells of 
the immune system to eliminate infected or tumorigenic cells (Igney and Krammer 2002). It is 
triggered by binding of ligands to specific death receptors (CD95, TNFR1, TRAIL-R1 and 
TRAIL-R2) on the target cells surface. The binding of the ligand leads to the recruitment of 
adaptor molecules on the cytosolic domain of the activated receptor. These bind to initiator 
caspase 8 and 10 leading to dimerisation of caspases leading to autocatalysis and activation 
of initiator caspases. This signaling complex is called “death-inducing signaling complex” 
(DISC). The initiator caspases subsequently cleave and activate effector caspases 3, 6 and 7 
(Ashkenazi 2002; Lavrik, Golks et al. 2005). 
 
1.3.3 The intrinsic pathway of apoptosis 
The intrinsic or mitochondrial pathway of apoptosis is triggered by DNA damage, oncogene 
activation or other intracellular apoptotic signals. The outer mitochondrial membrane is 
permeabilized and cytochrome C as well as other apoptotic factors is released into the 
cytosol. The permeabilization of the mitochondrial membrane is regulated by an interaction of 
anti- and pro-apoptotic molecules of the Bcl-2 family of proteins. After the release of 
mitochondrial proteins into the cytosol a multi-protein complex of Apaf-1 and cytochrome C 
molecules is formed. The so called apoptosome binds and activates the initiator caspase 9. 
In turn caspase 9 cleaves and activates effector caspases 3 and 7 (Riedl and Shi 2004; 
Gogvadze and Orrenius 2006). The intrinsic pathway as well can be activated by death 
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receptors. The Bcl-2 family protein BID can be cleaved by caspase 8. Cleaved BID activates 
the pro-apoptotic proteins Bak and Bax leading to permeabilization of the mitochondria 
(Korsmeyer, Wei et al. 2000).  
The effector caspase activated by both apoptotic pathways cleave a variety of cellular 
substrates leading to the characteristic biochemical and morphological changes of the 
apoptotic cell like chromatin condensation, DNA fragmentation or shrinking and 
fragmentation of the cell (Fischer, Janicke et al. 2003). 
 
Fig. 1.1 Apoptotic pathways: 
Apoptosis is initiated via two main pathways. The extrinsic pathway is triggered by binding of ligands 
to their respective death inducing receptor and following activation of caspase 8. Release of pro-
apoptotic proteins and cytochrome C from the mitochondria following different stress signals initiates 
the intrinsic pathway of apoptosis leading to activation of pro-caspase 9. The activation of both initiator 
caspases leads to processing of effector caspases with subsequent cleavage of target proteins and 
cell death. The extrinsic and intrinsic pathways are connected via the cleavage of Bid to tBid by 
caspase 8. Depending on the cell type activation of death receptors directly leads to activation of 
effector caspases (type I cells) or indirectly via the mitochondria (type II cells). 
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1.3.4 TRAIL receptors 
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor 
necrosis factor (TNF) superfamily of proteins, that was discovered in 1995 (Wiley, Schooley 
et al. 1995) and since then is under investigation as a biologically targeted anti-tumor protein 
since it induces apoptosis in a variety of human cancer cell lines while leaving normal cells 
unaffected (Walczak, Miller et al. 1999). In humans TRAIL can bind to four known membrane 
bound receptors, death receptor 4 (DR4)/TRAIL receptor-1 (Pan, O'Rourke et al. 1997), 
death receptor 5 (DR5)/TRAIL receptor-2 (Pan, Ni et al. 1997; Walczak, Degli-Esposti et al. 
1997), TRAIL receptor without an intracellular domain (TRID)/decoy receptor 1 
(DCR1)/TRAIL receptor-3 (Degli-Esposti, Smolak et al. 1997; Pan, Ni et al. 1997; Sheridan, 
Marsters et al. 1997), and TRAIL receptor-4/decoy receptor 2 (DCR2)/TRAIL receptor with a 
truncated death domain (TRUNDD) (Degli-Esposti, Smolak et al. 1997; Marsters, Sheridan et 
al. 1997; Pan, Ni et al. 1998). TRAIL receptor-3 and TRAIL receptor-4 do not possess an 
intracellular domain and have been proposed as competitive inhibitors of TRAIL induced 
apoptosis (Sheridan, Marsters et al. 1997). TRAIL receptor 1 and TRAIL receptor 2 on the 
other hand contain a cytoplasmic death domain capable of activating the extrinsic pathway of 
apoptosis by recruiting the death-inducing signaling complex (DISC) upon ligand binding and 
trimerization of the receptor (Hymowitz, 
Christinger et al. 1999). DISC includes FAS-
associated death domain protein (FADD), pro-
caspase 8, and possibly cellular FADD-like IL-1β-
converting enzyme inhibitory protein (cFLIP) 
(Kischkel, Lawrence et al. 2000; Sprick, Weigand 
et al. 2000). After autocatalytic cleavage and 
activation of pro-caspase 8 at the DISC 
downstream effector caspases are activated in 
type I cells (Kischkel, Lawrence et al. 2000). In 
type II cells intrinsic apoptosis can be triggered by 
cleavage of Bid (Barnhart, Lee et al. 2003). 
Finally TRAIL can also bind to osteoprotegerin 
(Emery, McDonnell et al. 1998), a soluble 
receptor for Receptor Activator of NF-κB Ligand 
(RANKL) (Fig. 1.2).  
Fig. 1.2 The human TRAIL receptors:  
Human TRAIL can bind to five different receptors. TRAIL receptor 1 and TRAIL receptor 2 can signal 
apoptosis via their cytoplasmatic death domain. Decoy receptor 1 is lacking a death domain while 
decoy receptor 2 has a truncated death domain unable to signal apoptosis. Osteoprotegerin is a 
soluble receptor for TRAIL. 
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The different sensitivity of normal and neoplastic cells towards TRAIL induced apoptosis may 
be due to several reasons. Messenger RNA of all TRAIL receptors is expressed throughout a 
wide variety of cells and tissues (Wiley, Schooley et al. 1995). Therefore the expression 
pattern of apoptosis signalling versus non signalling TRAIL receptors has been proposed as 
a way of regulation of sensitivity to TRAIL-induces apoptosis (Marsters, Sheridan et al. 1997; 
Pan, Ni et al. 1997; Pan, Ni et al. 1998) and has been confirmed for primary tumors of the 
gastrointestinal tract (Sheikh, Huang et al. 1999) and human breast cancer cell lines 
(Sanlioglu, Dirice et al. 2005). Another finding suggests that the cell cycle phase determines 
cell sensitivity towards TRAIL as was shown in human colon and lung cancer cell lines 
arrested in the G0/G1phase of the cell cycle (Jin, Dicker et al. 2002) may be due to differential 
expression of pro- and anti-apoptotic proteins during different cell cycle phases as has been 
shown in activated T cells (Algeciras-Schimnich, Griffith et al. 1999). The most prominent 
theories concerning regulation of TRAIL-induces apoptosis involve the differential expression 
of pro- and anti-apoptotic proteins within the targeted cells such as cFLIP, Bcl-2 family 
members, the ERK and Akt signaling pathways and the inhibitor of apoptosis proteins (IAPs). 
(Griffith, Chin et al. 1998; Shiiki, Yoshikawa et al. 2000; Nesterov, Lu et al. 2001; Fulda, 
Meyer et al. 2002; Vaculova, Hofmanova et al. 2006; Kim, Ricci et al. 2008). Since cFLIP 
binds competively to FADD its suppression can sensitize some cancer cells to TRAIL-
induced apoptosis (Geserick, Drewniok et al. 2008). In many tumor cell lines XIAP has been 
observed to be highly expressed and it may lead to TRAIL resistance by directly inhibiting 
caspases 3, 7 and 9, even in the presence of Smac/DIABLO (Deveraux, Takahashi et al. 
1997; Schimmer, Welsh et al. 2004). Anti-apoptotic members of the Bcl-2 family regulate 
sensitivity towards TRAIL as has been shown for Bcl-2 and Bcl-xL (Hinz, Trauzold et al. 
2000; Sinicrope, Penington et al. 2004) as well as for myeloid cell leukemia-1 protein (Mcl-1) 
(Clohessy, Zhuang et al. 2006). 
 
1.3.5 Inhibitor of apoptosis protein (IAP) family 
Originally IAP proteins were identified in baculoviruses. These insect viruses express IAP 
proteins to inhibit the apoptosis initiated by the infected host cell (Crook, Clem et al. 1993). 
Primarily IAPs were thought to function by regulating caspases, which are cysteine proteases 
that are involved in apoptosis. However IAPs also influence a multitude of other cellular 
processes, such as ubiquitin (Ub) –dependent signaling events that regulate activation of 
nuclear facor-κB (NF-κB) transcription. Until now eight human IAPs have been identified: 
XIAP, ILP-2, cIAP1, cIAP2, ML-IAP (Livin), NAIP, Survivin and Apollon. The defining feature 
of an IAP protein is the presence of the baculovirus IAP repeat (BIR) domain, a zinc-binding 
fold of approximately 70 amino acid residues that mediates protein-protein interactions 
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(Birnbaum, Clem et al. 1994; Hinds, Norton et al. 1999; Sun, Cai et al. 2000). IAPs of which 
there are eight in humans, carry between one and three copies of this domain (Fig. 1.3). 
 
Fig. 1.3 Inhibitor of apoptosis proteins (IAPs): 
The eight human inhibitor of apoptosis proteins are characterized by at least one BIR domain. BIR: 
Baculovirus IAP repeat, CARD: caspase recruitment domain, RING: really interesting new gene, ILP: 
IAP-like protein, cIAP cellular IAP. ML-IAP: melanoma IAP, NIAP: neuronal IAP, XIAP: X-linked IAP. 
 
 
Additionally XIAP, cIAP1, cIAP2 and Livin have a RING domain that provides them with Ub 
ligase (E3) activity (Yang, Fang et al. 2000) that can link target proteins to one or more 
ubiquitin residues. Moreover they carry an Ub-associated (UBA) domain through which they 
interact with ubiquitylated proteins (Gyrd-Hansen, Darding et al. 2008; Blankenship, 
Varfolomeev et al. 2009). Monoubiquitination of target proteins leads to functional changes 
and polyubiquitination in most cases leads to proteolytic degradation. Polyubiquitinated 
proteins are degraded in the proteasome, a multi protein complex (Hicke 2001; Vaux and 
Silke 2005). Only cIAP1 and cIAP2 carry a caspase recruitment domain (CARD) located 
between the BIR and the RING domain. Its function is currently unknown. 
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1.3.6 The IAP Survivin 
With a molecular size of 16.5 kDa Survivin is the smallest known member of the IAP family of 
anti-apoptotic proteins. Survivin contains a single BIR domain but no RING finger or other 
identifiable domain typically found in IAPs. In healthy tissues its expression is found during 
embryogenesis and in adults in vascular endothelial cells (Mesri, Morales-Ruiz et al. 2001) 
(Blanc-Brude, Mesri et al. 2003), polymorphonuclear cells (Altznauer, Martinelli et al. 2004), 
T cells (Okada, Bakal et al. 2004; Xing, Conway et al. 2004) and haematopoietic progenitor 
cells (Xing, Conway et al. 2004; Gurbuxani, Xu et al. 2005; Leung, Xu et al. 2007). Survivin 
has the ability to counteract with extrinsic and intrinsic mediators of apoptosis with effecting 
mechanisms such as withdrawal of IL-3 (Fukuda and Pelus 2004), stimulation of death 
receptors of the TNFR family like FAS (CD95) (Tamm, Wang et al. 1998), TNF-related 
apoptosis-inducing ligand (TRAIL) (Chawla-Sarkar, Bae et al. 2004). By binding to 
Smac/DIABLO (Sun, Nettesheim et al. 2005) it may regulating apoptosis directly by 
sequestering SMAC away from XIAP (Song, Yao et al. 2003) or preventing altogether its 
release from mitochondria (Ceballos-Cancino, Espinosa et al. 2007). Besides its anti-
apoptotic functions survivin plays a key role in modulating cell cycle dependent mechanisms 
such as cell division, cell stress response and cell cycle checkpoints with physical 
localisation to the mitotic spindle apparatus (Pennati, Folini et al. 2008). Therefore its 
properties tend to increase cell proliferation of tumor cells and also mutant cancer cells 
making survivin an attractive therapeutic target and diagnostic marker in a wide spectrum of 
malignancies.   
 
1.3.7 Smac/DIABLO 
The second mitochondria-derived activator of caspase (Smac) or direct IAP binding protein 
with low isoelectric point (pI) DIABLO was identified simultaneously by two groups in 2000 
(Du, Fang et al. 2000; Verhagen, Ekert et al. 2000). It resides within the mitochondrial 
intermembrane space and is subsequently released into the cytosol through semiselective 
permeability together with other mitochondrial proteins such as Omi, adenylate kinase-2, 
cytochrome c and apoptosis-inducing factor upon the induction of apoptosis. Bcl-family 
proteins are pivotal in this process as they may facilitate (i.e. Bid (Du, Fang et al. 2000; Li, 
Zhao et al. 2002), Bax and/or Bak (Du, Fang et al. 2000; Kandasamy, Srinivasula et al. 2003) 
or inhibit (such as Bcl-2 or Bcl-xL) (Du, Fang et al. 2000; Sun, Bratton et al. 2002) the 
release of apoptotic mediators. There are different ways in which Smac/DIABLO contributes 
to the apoptotic process. Smac can bind many different IAPs (i.e. XIAP, cIAP1, cIAP2 and 
Survivin) (Du, Fang et al. 2000). It is able to interact with IAPs by binding to Survivins BIR1 
(Gao, Zhang et al.; Sun, Nettesheim et al. 2005) as well as BIR2 and BIR3 domains of XIAP, 
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cIAP1 and cIAP2 (Chai, Du et al. 2000) and so preventing their interaction with caspases 3 
and 7 and in case of XIAP to  caspase 9 (Srinivasula, Hegde et al. 2001). Smac/DIABLO can 
alter levels of certain IAPs. For example it can enhance autoubiquitination of cIAP1 and      
cIAP2 resulting in their proteasomal degradation (Varfolomeev, Blankenship et al. 2007; 
Vince, Wong et al. 2007). Furthermore, Smac/DIABLO increases tumor necrosis factor alpha 
(TNFα) mRNA expression leading to autocrine stimulation of the extrinsic apoptotic pathway 
(Varfolomeev, Blankenship et al. 2007; Vince, Wong et al. 2007).  
 
1.3.8 Smac mimetics 
Determination of the specific biochemical structures involved in the IAP-Smac interaction has 
facilitated the development of Smac-like molecules. The crucial N-terminus of Smac has four 
residues (Ala-Val-Pro-Ile) that contact the BIR3 domain of XIAP, and this structure is 
stabilized by electrostatic and hydrophobic forces (Liu, Sun et al. 2000; Wu, Chai et al. 
2000). Once this structure was elucidated, the development of Smac mimetics, including 
effective nonpeptic mimetics that have advanced bioavailability and stability (Liu, Sun et al. 
2000; Wist, Gu et al. 2007), provided a variety of molecules that could serve as IAP 
antagonists. Several different groups of Smac mimetics can be distinguished: fusion peptides 
of the last four to eight N-terminal residues of Smac with various modifications, plasmid 
based polynucleotides coding for full-length Smac and peptic or nonpeptic small molecules 
mimicking Smac structure. 
 
1.3.9 Preclinical and clinical studies 
 
TRAIL 
The tumoricidal activity of TRAIL has been described in multiple preclinical trials carried out 
in vitro and in vivo using recombinant human TRAIL (rhTRAIL) on cell lines derived from both 
solid and hematologic malignancies, either alone or in combination with various 
chemotherapy agents or irradiation (Ashkenazi, Pai et al. 1999; Gazitt 1999; Kelley, Harris et 
al. 2001; Marini, Schmid et al. 2005). A way of directing TRAIL towards tumor cells is the 
creation of cell specific fusion proteins (Stieglmaier, Bremer et al. 2008). Combination 
therapy with conventional chemotherapy or radiotherapy where successful to overcome 
TRAIL resistance of tumors (Keane, Ettenberg et al. 1999; Mizutani, Yoshida et al. 1999; 
Nimmanapalli, Perkins et al. 2001). Bortezomib, a proteasome inhibitor approved for the 
treatment of multiple myeloma has been shown to have a pro-apoptotic effect in combination 
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with TRAIL possibly by its ability to increase p53 and TRAIL receptor-2 expression while 
decreasing cFLIP expression (Johnson, Stone et al. 2003; Sayers, Brooks et al. 2003; 
Williams and McConkey 2003). Bcl-xL, Mcl-1 and cFLIP have been downregulated by the 
kinase inhibitor sorafenib in several human leukemia sensitizing them to TRAIL-induced 
apoptosis while normal CD34+ bone marrow cells stay unaffected (Rosato, Almenara et al. 
2007). In human prostate cancer cells BH3I-2’ a Bcl-2 inhibitor induces apoptosis 
synergistically in the presence of TRAIL (Ray, Bucur et al. 2005). 
 To date clinical phase II trials for monoclonal TRAIL-R1 antibody TRM-1 (Mapatumumab) for 
treatment of non-small cell lung cancer and Non-Hodgekin’s lymphoma have been 
completed and the clinical phase II trial of recombinant human TRAIL AMG 951 for treatment 
of small cell lung cancer is still ongoing (http://clinicaltrials.gov/). 
 
Survivin 
Strong survivin expression is observed in the vast majority of cancers (Altieri 2003) and in 
patients with haematologic malignancies (Cong and Han 2004). In cancer elevated survivin is 
commonly associated with enhanced proliferative index (Sui, Dong et al. 2002; Takai, 
Miyazaki et al. 2002; Fields, Cotsonis et al. 2004), resistance to chemotherapy (Tran, Master 
et al. 2002; Zaffaroni, Pennati et al. 2002) and rate of tumor recurrence (Swana, Grossman 
et al. 1999).  
Besides classical diagnostic methods like reverse transcription polymerase chain reaction 
(RT-PCR), and flow cytometric analysis several new tools have been developed to establish 
survivin as a diagnostic biomarker like molecular beacon technology (Yang, Cao et al. 2005), 
recombinant nucleic acid-reporter gene-based assays (Caldas H, Altura RA 
WO2006066451;2006) and LabMAP technology (Lokshin A. US20070042405; 2007). 
Prominent strategies in targeting survivin in disease involve adenoviral expression of mutant 
survivin (Mesri, Wall et al. 2001), small hammerhead RNA (shRNA) (Caldas, Holloway et al. 
2006) or small inhibitory RNA (siRNA) (Uchida, Tanaka et al. 2004). Combinational treatment 
in association with chemotherapeutics like gemcitabine, peclitaxel or doxorubicin results in 
marked downregulation of survivin expression and tumor regression (Patents reviewed in 
(Kanwar, Kamalapuram et al. 2010)). 
A Phase II study with LY2181308 a modified antisense oligonucleotide for treatment of acute 
myeloid leukemia and an evaluation study for survivin mRNA as a marker in bladder cancer 
patients has been completed. The transcriptional survivin repressors YM155 finished phase 
II studies for treatment of solid tumors, melanoma and prostate cancer and EM-1421 finished 
phase I trials for several tumor types (http://clinicaltrials.gov/). 
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Smac mimetics 
Over the past few years evidence for the use of Smac mimetics in the treatment of neoplastic 
malignancies continues to accumulate. At this stage only a few small molecule Smac 
mimetics have entered Phase I clinical trial like AT-406, TL32711, HGS1029 and LCL161 for 
treatment of advanced solid tumors or GDC-0152 for non-Hodgkin’s lymphoma 
(http://clinicaltrials.gov/) but the effectiveness of a multitude of substances has been proven 
in vitro and in vivo. For example peptides successfully induce apoptosis in human breast 
cancer cells in combination with paclitaxel, etoposide or doxorubicin (Arnt, Chiorean et al. 
2002) and augmented TRAIL induced apoptosis in JURKAT cells (Guo, Nimmanapalli et al. 
2002). Polynucleotides increased the leukemia cell lines K562 and CEM sensitivity to both 
UV light-induced and TRAIL-induced apoptosis (Jia, Patwari et al. 2003) and sensitized 
JURKAT cells to TRAIL- and epothilone-induced apoptosis (Guo, Nimmanapalli et al. 2002). 
Small molecules sensitized human glioblastoma T98G cells to TRAIL induced apoptosis and 
HeLa cells to TNFα-induced apoptosis (Li, Thomas et al. 2004). Finally in female C.B-17-
Prkdcscid mice Smac mimetic treatment was able to significantly reduce tumor growth rate 
(Eiseman, Lan et al. 2005). 
 
1.4 Objectives 
Aim of the work is the identification and characterization of possible therapeutic targets and 
diagnostic markers in mastocytosis with special attention to pro- and anti-apoptotic proteins. 
Therefore the human neoplastic mast cell lines HMC-1.1 and HMC-1.2 carrying one 
respectively two activating mutations in the tyrosine kinase receptor KIT (CD117) were 
analyzed for the expression of members of the inhibitor of apoptosis protein (IAP) family and 
the expression of the pro-apoptotic TNF-related apoptosis-inducing ligand receptors   
(TRAIL-R1 and TRAIL-R2) which could be of future use as diagnostic markers or therapeutic 
targets in mastocytosis. With respect to ongoing research with recently generated mice 
carrying a mutant KIT receptor and so resembling the situation in human mastocytosis 
patients (Gerbaulet, Wickenhauser et al. 2010) the biological function of the murine TRAIL-R 
on murine bone marrow derived mast cells was characterized in this work. In two different 
approaches the combinational targeting of members of the IAP family of proteins and the use 
of either TRAIL or tyrosine kinase inhibitors as stimuli for the extrinsic respectively intrinsic 
pathway of apoptosis in neoplastic human mast cells were analyzed to make way for future 
investigation of treatment options of neoplastic mast cells diseases. 
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2 Results 
 
2.1 Expression of pro- and anti-apoptotic molecules in mast cells 
Identification of pro- or anti-apoptotic molecules differentially expressed in neoplastic mast 
cells compared to healthy tissue could be a step in enhancing existing therapies for 
mastocytosis patients. Since the constitutive activation of the tyrosine kinase KIT is a 
hallmark of neoplasia in mastocytosis the two neoplastic mast cell lines HMC-1.1 and    
HMC-1.2 carrying one respectively two mutations in the KIT gene were analyzed for 
expression of pro- and anti-apoptotic molecules.  
The IAP Survivin was found to be stronger expressed in HMC-1.2 cells indicating a link 
between KIT activation and Survivin expression. Further primary human mast cells 
generated from umbilical cord blood or isolated from skin were compared to different mast 
cell and non-mast cell lines for Survivin expression on the mRNA and protein level showing 
very low expression in the primary healthy mast cells. Comparison of bone marrow samples 
of mastocytosis patients and healthy donors revealed a significantly higher Survivin 
expression in mast cell infiltrates of the mastocytosis patients while expression in infiltrates of 
healthy donors was almost undetectable. This pattern highlights Survivin expression as to be 
more disease-related than for example the recently analyzed anti-apoptotic bcl-2 family 
protein Mcl1 (Aichberger, Mayerhofer et al. 2007) which is expressed in normal and 
neoplastic transformed mast cells.   
In a second approach human neoplastic mast cells were analyzed for the expression of the 
TNF-related apoptosis-inducing ligand receptors (TRAIL-R1 and TRAIL-R2). Both cell lines 
show expression of both receptors on mRNA and protein level, and their expression on the 
cell surface was confirmed by flow cytometric analysis. With regard to a recently generated 
mouse model of mastocytosis murine mast cells were analyzed for expression of the murine 
TRAIL receptor and its regulation after KIT- and FcεR-activation. The murine TRAIL receptor 
is expressed on murine bone marrow derived mast cells and in accordance with findings in 
human mast cells (Berent-Maoz, Piliponsky et al. 2006; Berent-Maoz, Salemi et al. 2008) its 
expression is upregulated after IgE-dependent activation. Here a dose dependent regulation 
of the murine TRAIL receptor expression after activation of KIT with stem cell factor has been 
shown. 
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2.1.1 Expression of TRAIL receptors in mast cells 
2.1.1.1 Expression of TRAIL and its receptors in human neoplastic 
mast cells 
The expression of the TRAIL receptors TRAIL-R1 and TRAIL-R2 was analyzed in both 
clones of the human mast cell line HMC-1. To identify a potential differential expression both 
cell lines were analyzed for mRNA- and protein-expression of the receptors. The surface 
expression of both TRAIL receptors on HMC-1 cells was determined by flow cytometry. 
Furthermore the expression of TRAIL mRNA and protein was measured since recent findings 
showed TRAIL expression in human neoplastic mast cells with still unclear mechanisms of 
regulation, release or function (Berent-Maoz, Salemi et al.). Both cell lines showed 
comparable expression levels with no significant differences of TRAIL, TRAIL-R1 and  
TRAIL-R2 mRNA, protein and surface expression of the receptors. 
The human neoplastic mast cell lines HMC-1.1 and HMC-1.2 were analyzed for expression 
of mRNA of TRAIL and its receptors TRAIL-R1 and TRAIL-R2. Both cell lines were seeded in 
complete medium and harvested during logarithmic growth. The mRNA was extracted and 
subjected to RT-PCR. Both cell lines express mRNA of TRAIL and the receptors TRAIL-R1 
and TRAIL-R2. The densitometric analysis of several PCR gels showed no significant 
difference between PCR products of both cell lines (Fig. 2.1). 
 
 
 
 
 
Fig. 2.1 Human neoplastic mast cells show RNA expression of trail and its receptors: 
RT-PCR products of RNA isolated from HMC-1.1 and HMC-1.2 cells separated on a 2% agarose gel. 
(1, 100 bp Ladder; 2+3, gapdh 226 bp; 4+5, trail 510 bp; 6+7, trail-r1 415 bp; 8+9, trail-r2 437 bp). 
Data are representative of three independent experiments, all of which had similar results. 
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Both neoplastic mast cell lines were subjected to Western blot analysis with specific 
antibodies against TRAIL and its receptors TRAIL-R1 and TRAIL-R2. Expression of all three 
proteins can be detected in cell lysates of both cell lines harvested during logarithmic growth 
(Fig. 2.2). 
 
Fig. 2.2 Expression of TRAIL and its receptors can be detected in cell lysates of human 
neoplastic mast cells: 
Western blot analysis of HMC-1.1 and HMC-1.2 cell lysates was performed with specific antibodies 
against TRAIL, TRAIL-R1 and TRAIL-R2. β-Actin was used as a loading control. 
Data are representative of three independent experiments with similar results. 
 
Surface expression of TRAIL-R1 and TRAIL-R2 was shown on HMC-1.1 and HMC-1.2 cells 
by staining both cell lines with fluorescent antibodies specific for the receptors (Fig. 2.3).  
 
Fig. 2.3 Human neoplastic mast cells express TRAIL receptors on the cell surface: 
HMC-1.1 and HMC-1.2 cells where labeled with PE-conjugated antibodies against TRAIL-R1,    
TRAIL-R2 (black line) or PE-conjugated isotype controls (grey line). Cells were analyzed by flow 
cytometry. Data are representative of three independent experiments with similar results. 
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2.1.1.2 Expression of TRAIL-R in murine mast cells 
 
TRAIL-R is expressed on murine mast cells and its expression is 
upregulated by stem cell factor and IgE dependent activation 
To analyze the effect of c-KIT activation and IgE-dependent activation on TRAIL-R-
expression of murine mast cells, bone marrow-derived mast cells (BMMC)  were either 
incubated with SCF or stimulated with IgE/anti-IgE or both for 24 h. Cells were harvested and 
stained with TRAIL-R specific or isotype antibodies and analyzed by flow cytometry         
(Fig. 2.4 A). Mean fluorescence was calculated and plotted as a percentage of the control 
(Fig. 2.4 B), showing that incubation with SCF of IgE-dependent stimulation increases 
TRAIL-R expression on BMMC but a combination of both has no additive effect. 
Fig. 2.4 TRAIL-R expression on BMMC is upregulated by SCF and IgE dependent activation: 
(A) BMMC were incubated with SCF, activated by 1 µg/ml IgE/anti-IgE or both for 24 h. TRAIL-R 
expression was measured by flow cytometry after staining of cells with PE conjugated TRAIL-R 
specific antibodies (black graphs) or PE conjugated isotype control (grey line). Data are representative 
of three independent experiments, all of which had similar results. (B) Mean fluorescence of stimulated 
and unstimulated cells was calculated. Results are presented as percent expression of TRAIL-R on 
stimulated cells compared to unstimulated cells (defined as 0%) and expressed as mean +/- SEM of 
three independent experiments.  
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SCF dependent upregulation of TRAIL-R is dose dependent 
To confirm the first flow cytometric results, RT-PCR from mRNA isolated from SCF treated 
BMMC after 24 h was performed and a clear increase of PCR product was observed  
(Fig.2.5 A). Further, BMMC were incubated with SCF for 24 h and analyzed by flow 
cytometry. When BMMC were incubated with increasing concentrations of SCF for 24 h an 
increase of TRAIL-R expression was detected showing a correlation between receptor 
expression and level of c-KIT activation (Fig. 2.5 B, C). 
 
Fig. 2.5 Upregulation of TRAIL-R on BMMC by SCF is dose dependent: 
RT-PCR was performed of RNA isolated from BMMC incubated with SCF (30 ng/ml) for 24 h 
compared to untreated control cells (A). PCR products where analyzed on a 1% agarose gel (TRAIL-R 
579 bp, GAPDH 226 bp). 
BMMC where incubated with different concentrations of SCF (0, 5, 10, 30 and 100 ng/ml) for 24 h and 
surface expression of TRAIL-R was analyzed by flow cytometry after staining of cells with PE-
conjugated antibody against TRAIL-R (black lines) or PE-conjugated isotype control antibody (grey 
line) (B). 
Mean fluorescence of stimulated and unstimulated cells was calculated (C). Results are presented as 
percent expression of TRAIL-R on stimulated cells compared to unstimulated cells (defined as 0%) 
and expressed as mean +/- SEM of three independent experiments. 
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2.1.2 Human neoplastic mast cells express inhibitor of apoptosis         
proteins (IAPs) 
To determine proteins involved in apoptosis which are differently expressed under the control 
of the active tyrosine kinase KIT, the two human neoplastic mast cell lines HMC-1.1 and 
HMC-1.2 were analyzed. Both cell lines where seeded in complete medium, harvested 
during logarithmic growth and subjected to Western blot analysis with antibodies specific for 
X-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis 1 and 2 (cIAP1, cIAP2) 
and Survivin, the second mitochondria-derived activator of caspase (Smac), the bcl-2 family 
members Mcl1 and Noxa, the cellular FLICE-like inhibitory protein (cFLIP) and β-Actin as 
loading control. Resulting films were analyzed densitometrically.  
The expression of almost all proteins analyzed except Survivin was found to be equal in both 
HMC-1 subclones. Slight differences in single blots like seen below for Noxa (Fig. 2.6) could 
not be confirmed over the whole range of experiments. A pronounced expression of the IAP 
Survivin in HMC-1.2 cells was observed in all repeated experiments and was highly 
significant after densitometric analysis. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6 Expression of IAPs in neoplastic human mast cells: 
Cell lysates of HMC-1.1 and HMC-1.2 cells were analyzed with 
specific antibodies against XIAP, Smac, cIAP1, cIAP2, Noxa, 
Mcl1, cFLIP and Survivin. β-Actin was used as a loading control. 
Data are representative of at least four independent experiments 
with similar results. 
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2.1.3 Expression of Survivin in human mast cells 
2.1.3.1 Expression of Survivin mRNA and protein in human mast  
cells 
Different human mast cells were analyzed for expression of survivin mRNA (Fig. 2.7 A) and 
protein (Fig. 2.7 B) to study a possible link between Survivin expression and neoplasia. 
Human skin mast cells, human umbilical cord blood-derived mast cells and the mast cell line 
LAD-2 which is stem cell factor dependent and carries no activating KIT mutations showed 
low expression of survivin mRNA expression compared to HMC-1.2 cells, the basophilic 
KU812 cell line and JURKAT T cells. Western blot analysis performed with antibodies 
specific for Survivin showed low expression of Survivin protein in human umbilical cord 
blood-derived mast cells and LAD-2 cells compared to HMC-1.2, KU812 and JURKAT T 
cells.  
Survivin is expressed in all cells analysed. The amount of mRNA and protein correlates with 
the rate of proliferation. 
 
Fig. 2.7 Increased expression of survivin mRNA (A) and protein (B) in human neoplastic 
mast cells compared to primary mast cells: 
RT-PCR was performed of mRNA isolated from different mast cell lines (HMC-1.2, KU812, LAD-2), 
primary human skin mast cells (skin MC) and the control cell line JURKAT with primers specific for 
survivin and gapdh (A). Fluorescence of ethidium bromide-stained RT-PCR products was measured 
by densitometry (upper graph). Results are presented as relative expression of survivin mRNA 
compared to the most pronounced expression KU812 cells (defined as 1.0) of at least three 
independent experiments with similar results. 
Western blot analysis was performed of cell lysates of umbilical cord blood-derived mast cells 
(CBMC), different mast cell lines (LAD-2, HMC-1.2, KU812) and the control fell line JURKAT with a 
Survivin-specific antibody. β-Actin served as a loading control (B). Data are representative of three 
independent experiments with similar results. 
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2.1.3.2 Expression of Survivin protein in mast cells infiltrating the 
bone marrow of patients with Mastocytosis 
To verify the relevance of upregulated survivin expression in vivo, bone marrow sections with 
mast cell infiltrates from Mastocytosis patients were screened for co-expression of mast cell 
tryptase and Survivin. In all samples from Mastocytosis patients Survivin expression was 
strongly pronounced compared to samples from healthy donors with reactive bone marrow 
infiltrates (Fig. 2.8).  
Mast cells in bone marrow-infiltrates of patients with mastocytosis do not show elevated 
staining of the interphase marker Ki67 but significant increase of the marker of G1 arrest p21 
compared to mast cells in reactive bone marrow infiltrates (Baldus, Zirbes et al. 2004). 
Further p21 expression in mast cells is linked to c-KIT activity (Panzenbock, Bartunek et al. 
1998), so elevated Survivin expression could be due to the neoplastic state of the cells not 
their higher rate of proliferation. Serial sections of bone marrow specimen where stained with 
antibodies specific for tryptase and survivin to analyze a possible co-expression. The double 
staining revealed no co-localization of tryptase and Survivin in bone marrow sections of 
healthy patients while most mastocytosis patients showed Survivin expression in at least 
30% of infiltrates (Fig. 2.8 A-D).  
 
 
 
Fig. 2.8 Expression of Survivin protein in mast cells infiltrating the bone marrow of patients 
with mastocytosis: 
Paraffin embedded bone marrow sections of mast cell infiltrates from patients with Mastocytosis were 
stained for mast cell tryptase (A, C) and Survivin (B, D). 
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To determine a statistical significance of these findings the bone marrow sections were 
scored for their level of Survivin antibody reactivity (Table 2.1): 0, mastocytosis: no reactivity 
of dense focal infiltrates of mast cells, reactive bone marrow (RBM): no reactivity of mast 
cells; 1, mastocytosis: reactivity in <30% of infiltrates, RBM: reactivity in <30% of mast cells; 
2, reactivity in 30% to 70% of infiltrates or mast cells; 3, reactivity in >70% of infiltrates or 
mast cells. While a high Survivin expression (score 1-3) was only observed in patients with 
mastocytosis, Survivin expression score was 0 in healthy (RBM) donors. The serum tryptase 
level of the patients has a tendency to correlate with the degree of survivin expression but 
this was not statistical significant. 
 
Table 2.1 Expression of Survivin in human Mastocytosis: 
Paraffin-embedded bone marrow sections of 16 patients with mastocytosis were analyzed by 
immunohistochemistry and compared with 3 control patients with reactive bone marrow (RBM). The 
diagnosis of mastocytosis was made on the basis of published criteria. Out of the 16 patients, 15 
patients had indolent systemic mastocytosis and one patient had aggressive systemic mastocytosis. 
Informed consent was obtained from all before bone marrow biopsies were performed. 
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2.2 Control of mast cell survival by pro- and anti-apoptotic 
molecules 
After identifying Survivin as an anti-apoptotic protein being differentially expressed in human 
neoplastic mast cells depending on the level of KIT activation and TRAIL receptors being 
expressed in both subclones and murine mast cells, the susceptibility of these cells to TRAIL 
induced apoptosis was evaluated. HMC-1.1 and HMC-1.2 cells were incubated with 
recombinant human TRAIL and exhibited comparable low but significant loss of viability and 
an increasing number of apoptotic cells was detectable after at least 24 h of incubation. 
In murine bone marrow-derived mast cells TRAIL alone failed to induce apoptosis. Only co-
incubation with stem cell factor raised their susceptibility and significant apoptosis was 
measurable at 72 h of incubation. 
In two approaches anti-apoptotic proteins were targeted in neoplastic human mast cells 
before apoptosis was induced by either tyrosine kinase inhibitors or TRAIL. 
First the Survivin expression of HMC-1.2 cells was downregulated by Survivin-specific 
siRNA. This alone abolished proliferation and reduced their viability. Furthermore 
downregulation of Survivin combined with either tyrosine kinase inhibitor treatment or TRAIL 
induced apoptosis resulted in a synergistic loss of viability. 
In a second approach the Smac mimetic LCL161 was used to target the IAPs XIAP, cIAP1 
and cIAP2 in HMC-1.1 and HMC-1.2 cells. LCL161 alone led to accumulation of HMC-1 cells 
in the G1 phase of the cell cycle and to inhibited proliferation. Combination of LCL161, the 
tyrosine kinase inhibitor PKC412 or TRAIL reduced viability and increased the rate of 
apoptotic cells in a synergistical manner after 24 h.  
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2.2.1 TRAIL reduces viability of human neoplastic mast cells and 
induces apoptosis 
To investigate a dose dependent sensitivity of HMC-1 cells towards TRAIL induced apoptosis 
human neoplastic mast cells were incubated with human recombinant FLAG-tagged TRAIL 
at concentrations of 250 and 500 ng/ml. Furthermore a difference in sensitivity between both 
subclones should be examined. The percentage of viable cells was determined by propidium 
iodide uptake (Fig 2.9 A) and the rate of apoptosis by binding of Annexin-V (Fig. 2.9 B). After 
48 h of incubation cells were analyzed by flow cytometry. Both the loss of viability and the 
increase of apoptotic cells were significant and dose dependent in HMC-1.1 and HMC-1.2 
cells but there was no significant difference in loss of viability or rate of apoptosis between 
both cell lines.  
 
 
 
Fig. 2.9 TRAIL induces apoptosis in neoplastic human mast cells and reduces their viability: 
HMC-1.1 and HMC-1.2 cells were incubated with TRAIL-FLAG for 48 h. Viability and apoptosis was 
measured by FACS analysis after staining with APC-labeled Annexin-V and propidium iodide. 
Data are representative of at least three independent experiments. 
P values ≤ 0.05 where considered as significant (*). 
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2.2.2 TRAIL induced loss of viability of BMMC is increased by SCF 
To examine the effect of TRAIL on primary murine mast cells, bone marrow-derived mast 
cells were incubated with 500 ng/ml TRAIL, 40 ng/ml of the inhibitor or RNA synthesis 
actinomycin D, a combination of both or medium alone for up to 72 h. Actinomycin D at low 
doses has been described to sensitize mast cells to Fas mediated apoptosis with only a 
slight impact on their viability (Hartmann, Wagelie-Steffen et al. 1997). 
While TRAIL alone was capable of reducing viability of BMMC to a small amount this effect 
was more pronounced under co-treatment with actinomycin D. Incubation of BMMC with SCF 
enhanced viability loss of BMMC (Fig. 2.11). 
 
 
 
 
Fig. 2.11 TRAIL induced loss of viability of BMMC is increased by SCF: 
BMMC were incubated with medium alone, TRAIL-FLAG (500 ng/ml), Actinomycin D (40 ng/ml) or a 
combination of TRAIL-FLAG and Actinomycin D (40 ng/ml) for up to 72 h. Cells were stained with 
propidium iodide. Viability was measured by flow cytometric analysis. 
Data are representative of three independent experiments. 
P values ≤ 0.05 where considered as significant (*). 
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2.2.3 TRAIL-induced apoptosis of BMMC is increased by SCF 
When BMMC were incubated with FLAG-tagged recombinant TRAIL for three days and 
apoptosis was measured by flow cytometry after Annexin-V and propidium iodide staining, 
significant increase of apoptosis was detectable after 48 h. However the rate of apoptosis is 
very low compared to human neoplastic mast cells used in this thesis. Co-treatment of 
BMMC with the inhibitor of transcription actinomycin D increased the rate of apoptosis 
slightly. When BMMC were incubated in medium plus SCF, a marked increase of apoptotic 
BMMC under TRAIL treatment could be observed, even more pronounced when co-treated 
with actinomycin D (Fig. 2.10). 
 
 
 
 
Fig. 2.10 TRAIL-induced apoptosis of BMMC is increased by SCF: 
BMMC were incubated with medium alone, TRAIL-FLAG (500 ng/ml), Actinomycin D (40 ng/ml) or a 
combination of TRAIL-FLAG and Actinomycin D for up to 72 h. Cells were stained with Annexin-V. The 
rate of apoptosis was measured by flow cytometric analysis. 
Data are representative of three independent experiments. 
P values ≤ 0.05 where considered as significant (*). 
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2.2.4 Downregulation of Survivin increases mast cells sensitivity 
towards apoptotic stimuli 
HMC-1.2 cells were transfected with the Survivin-specific siRNA expressing plasmid pSuper-
Survivin (Lens, Wolthuis et al. 2003) or the Luciferase-specific siRNA expressing plasmid 
pSuper-Luc (Butz, Ristriani et al. 2003). After 24 h cells were harvested and subjected to 
Western blot analysis which showed the marked downregulation of Survivin protein in 
pSuper-Survivin transfected cells (Fig. 2.12). Downregulation of Survivin abolished HMC-1.2 
proliferation as determined by cell count on day 1 and 2 post transfection of three 
independent transfections with 3 respective 6 µg of pSuper-Survivin or pSuper-Luc. 
 
Fig. 2.12: Survivin protein expression in HMC-1.2 cells is reduced in pSuper-Survivin 
transfected HMC-1.2 cells (A). Rate of proliferation of pSuper-Survivin transfected cells is 
reduced compared to pSuper-Luc transfected cells (B): 
Western blot analysis of HMC-1.2 cell lysates was performed with a specific antibody against Survivin. 
β-Actin served as a loading control. 
Proliferation was calculated for each transfection by counting cells of three independent transfections 
after 24 and 48 h. The increase of cell number of cells transfected with 6 µg pSuper-Luc was defined 
as 100%.   
Data are representative of three independent experiments. 
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HMC-1.2 cells transfected with 3 µg pSuper-Survivin or pSuper-Luc were incubated with 250 
ng/ml TRAIL-FLAG, the tyrosine kinase inhibitors Nilotinib (7 µM) and PKC412 (1 µM) or 
medium alone. Propidium iodide uptake of cells was measured by flow cytometry after 48 h 
of culture. The loss of viability in pSuper-Survivin transfected cells was significantly increased 
compared to pSuper-Luc transfected cells (Fig. 2.13). 
 
Fig. 2.13: pSuper-Survivin transfected HMC-1.2 cells show reduced viability compared to 
pSuper-Luc transfected cells: 
HMC-1.2 cells were transfected with 3 µg of pSuper-Survivin or pSuper-Luc. After 48 h incubation with 
TRAIL-FLAG, Nilotinib, PKC412 or medium alone, cells were harvested. Cells were stained with 
propidium iodide and their viability was measured by flow cytometric analysis. 
Data are representative of three independent experiments. 
P values ≤ 0.05 where considered as significant (*). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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2.2.5 The Smac mimetic LCL161 inhibits proliferation of neoplastic 
human mast cells 
When incubated with the Smac mimetic LCL161 proliferation of HMC-1.1 and HMC-1.2 cells 
is inhibited in a dose dependent manner as was determined by cell count during two days of 
incubation (Fig. 2.14 A,B). While concentrations up to 10 µM of LCL161 only had moderate 
influence on both HMC-1 clones’ proliferation, it was inhibited at a concentration of 50 µM. 
When incubated with the Smac mimetic LCL161 for 24 h the cell cycle of HMC-1.2 cell shifts 
from the G2 phase towards the G1 and sub-G1 phase (Fig. 2.14 C). 
 
Fig. 2.14 LCL161 inhibits proliferation of HMC-1 cells in a dose-dependent manner: 
HMC-1.1 and HMC-1.2 were incubated with various concentrations of LCL161 for 48 h. Cell numbers 
and rate of proliferation were determined by manual cell count at time points indicated (A). Rate of 
proliferation was calculated from cell count at 0 and 48 h (B). 
For the cell cycle analysis cells where incubated with various concentrations of LCL161 for 24 h. Cells 
were fixed with ethanol and stained with propidium iodide to determine cell cycle phases by flow 
cytometry. (Cell cycle phases are indicated by bars in the diagrams: s.G: sub G peak; G1: Gap 1 
phase; S: Synthesis phase; G2: Gap 2 phase) (C). 
Data are representative of three independent experiments. 
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2.2.6 LCL161 does sensitize neoplastic human mast cells to TRAIL 
and PKC412 
HMC-1.1 and HMC-1.2 cells were incubated with LCL161, Flag-tagged recombinant TRAIL 
or a combination of both for 72 h. Loss of viability was determined by flow cytometry. Both 
stimuli alone were sufficient to reduce viability in both cell lines and their combination 
resulted in a synergistic effect. 
Fig. 2.16 LCL161 and TRAIL reduce viability of HMC-1 cells in a synergistic manner: 
HMC-1 cells were incubated with LCL161 and TRAIL-FLAG for 72 h. Cells were stained with 
propidium iodide and their viability was measured by flow cytometric analysis. 
Data are representative of three independent experiments. 
P values ≤ 0.05 where considered as significant (*). 
 
Both HMC-1 subclones were incubated with LCL161, Flag-tagged recombinant TRAIL or a 
combination of both for 72 h and the rate of apoptosis was determined by flow cytometry. In 
both cell lines TRAIL and LCL161 were able to induce apoptosis and their combination 
resulted in a synergistic effect. 
Fig. 2.17 LCL161 and TRAIL induces apoptosis of HMC-1 cells in a synergistic manner: 
HMC-1 cells were incubated with LCL161 and TRAIL-FLAG for 72 h. Cells were stained with 
propidium iodide and Annexin-V. The rate of apoptosis was measure by flow cytometric analysis. 
Data are representative of three independent experiments. 
P values ≤ 0.05 where considered as significant (*). 
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HMC-1.1 and HMC-1.2 cells were incubated with LCL161, PKC412 or a combination of both 
for 72 h and the loss of viability was determined by flow cytometry. Both stimuli alone were 
sufficient to reduce viability in both cell lines and their combination resulted in a synergistic 
effect. 
 
Fig. 2.18 LCL161 and PKC412 reduce viability of HMC-1 cells synergistically: 
HMC-1 cells were incubated with LCL161 and TRAIL-FLAG for 72 h. Cells were stained with 
propidium iodide. Viability was analyzed by flow cytometric analysis. 
Data are representative of three independent experiments. 
P values ≤ 0.05 where considered as significant (*). 
 
Both HMC-1 subclones were incubated with LCL161, PKC412 or a combination of both for 
72 h and the rate of apoptosis was determined by flow cytometry. In both cell lines TRAIL 
and LCL161 were able to induce apoptosis and their combination resulted in a synergistic 
effect. 
 
Fig. 2.19 LCL161 and PKC412 induce apoptosis of HMC-1 cells synergistically: 
HMC-1 cells were incubated with LCL161 and PKC412 for 72 h. Cells were stained with propidium 
iodide and Annexin-V. The rate of apoptosis was analyzed by flow cytometric analysis. 
Data are representative of three independent experiments. 
P values ≤ 0.05 where considered as significant (*). 
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3 Discussion 
Mastocytosis is a rare human disease characterized by the pathological accumulation of 
mast cells in various tissues. Different variations of mastocytosis can be distinguished by 
localization and severity of mast cell infiltration and proliferation. While in cutaneous 
mastocytosis mast cell infiltrates are restricted to the skin, mast cells in systemic 
mastocytosis can additionally infiltrate internal organs in particular the bone marrow. 
Increased release of mast cell mediators in patients with mastocytosis can cause pruritus, 
nausea, diarrhea or dizziness. In cases of systemic mastocytosis progressive mast cell 
infiltration can lead to severe symptoms like osteoporosis or organ failure. According to the 
WHO an important criterion for diagnosis of systemic mastocytosis is the detection of the 
activating D816V point mutation of the c-KIT receptor. Since no curative treatment for 
Mastocytosis is available yet, therapy options focus on inhibition of mediator release from 
mast cells and on control of mast cell numbers. Because increase of mast cell numbers of 
mastocytosis patients results from altered cell proliferation and dysregulated apoptosis, 
targeting the apoptotic pathways could provide an additional tool alongside conventional 
treatment with tyrosine kinase inhibitors. 
This work presents novel approaches for inhibiting the survival of neoplastic mast cells by 
targeting the cells’ apoptotic apparatus. Investigation of anti-apoptotic molecules showed a 
distinct correlation of expression of a single molecule with the state of disease. Immuno-
staining of mast cells from bone marrow infiltrates of patients with mastocytosis have been 
shown to express elevated levels of the anti-apoptotic protein Survivin compared to those of 
healthy donors. Higher c-KIT activation in neoplastic mast cell lines is associated with higher 
Survivin expression. The regulation of expression of the pro-apoptotic TRAIL receptor by     
c-KIT activation has been shown on murine mast cells. By use of siRNA the expression of 
Survivin in neoplastic mast cells was downregulated. Treatment with tyrosine kinase 
inhibitors or a soluble TRAIL-R ligand lead to markedly enhanced loss of viability of 
neoplastic mast cells compared to mast cells with normal levels of Survivin. When neoplastic 
mast cells were pre-treated with LCL161, a mimetic of the pro-apoptotic protein Smac the 
induction of apoptosis and reduction of viability by treatment either with the tyrosine kinase 
inhibitor PKC412 or soluble TRAIL was increased in a synergistic manner. These results 
point out the importance of Survivin as a molecular marker of neoplastic transformed mast 
cells and the effectiveness of intervention in apoptosis regulation for the treatment of 
systemic mastocytosis providing a promising new therapeutic approach. 
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3.1 Identification of novel therapeutic targets in mastocytosis:                              
Inhibition of survival of neoplastic mast cells by targeting of 
IAPs and TRAIL 
Altered expression of pro- and anti-apoptotic proteins has been observed in many neoplastic 
malignancies. It has been reported that bone marrow mononuclear cells of patients with 
mastocytosis express higher amounts of TRAIL-R mRNA (D'Ambrosio, Akin et al. 2003) and 
neoplastic human mast cells express functional TRAIL receptors (Berent-Maoz, Piliponsky et 
al. 2006). This thesis reports that activation of c-KIT enhances TRAIL-R expression and mast 
cells susceptibility towards TRAIL induced apoptosis which is even more pronounced in 
combination with tyrosine kinase inhibitors or inhibition of anti-apoptotic proteins. Further the 
inhibitor of apoptosis protein Survivin was found to be highly expressed in neoplastic mast 
cells in vitro and in vivo making it an interesting candidate for a diagnostic marker. Survivin 
downregulation enhanced the effect of tyrosine kinase inhibitors and TRAIL as did the 
inhibition of XIAP, cIAP1 and cIAP2 by the Smac mimetic LCL161. 
 
3.1.1 Choice of models for mast cell investigation 
For the investigation of normal human mast cells in vitro it is necessary to obtain a pure 
culture either by isolation of mature mast cells from tissue or by generation of mast cells from 
their immature progenitors. Mature human mast cells can be isolated for example from the 
skin, the intestine or the lung. Isolation of mast cells generally does not yield high cell 
numbers and the cells generally do not divide or survive for a longer time. To generate mast 
cells from the pools of progenitor cells for example from umbilical cord-blood or peripheral 
blood is extremely time consuming and since culture conditions are not clearly standardized 
different media compositions used produce mast cells with different phenotypes. Therefore 
the use of permanent cell lines still is the first choice for the in vitro study of human mast cell 
functions. Available today are the stem cell factor dependent mast cell line LAD-2 
(Kirshenbaum, Akin et al. 2003) and the stem cell factor independent mast cell line HMC-1 
with their subclones HMC-1.1 and HMC-1.2 carrying one respective two activating c-KIT 
mutations. In this work the HMC-1 cell lines isolated from a case of mast cell leukemia where 
used. These cells represent the standard tool for investigation of neoplastic mast cells 
resembling mast cells in mastocytosis patient and are widely used for the development of 
therapies. As a control cell line the basophilic KU812 cell line was used. KU812 cells share 
characteristics with basophiles like IL-3 expression and mast cells like expression of tryptase. 
KU812 cells express functional c-KIT and are sensitive towards tyrosine kinase inhibitors. 
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For the murine system two immature mast cell lines are used. The P-815 cell line is carrying 
an activating c-KIT mutation resembling the situation in the HMC-1.1 line. The cell line C57 
grows independently of c-KIT activity and therefore is unsuitable for the investigation of c-KIT 
dependent mast cell disorders. On the other hand the generation of primary mast cells from 
mice is well established and the standard protocols for the generation of bone marrow-
derived and peritoneal mast cells are less time consuming and generate high yields of mast 
cells of reproducible properties. Here BMMC from wild type animals were used for functional 
studies which were taken from animals of the same age and all cell preparations were 
routinely checked for uniform morphology and unvarying expression of mast cells surface 
markers. 
 
3.1.2 Detection of apoptosis 
Several methods for the detection of apoptosis are available. Qualitative analysis of 
apoptosis of in situ samples can be done by identification of cytoplasmic condensation, 
chromatin condensation and segregation with a transmission electron microscope. Light 
microscopic analysis of cells can reveal morphological changes like membrane blebbing or 
nucleus fragmentation which can be visually enhanced by additional staining with unspecific 
DNA dyes like DAPI (4,6-diamidino-2-phenylindole) or apoptosis specific staining of 
fragmented DNA by terminal-uridine-nick-end-labeling (TUNEL). Quantitative analysis of 
apoptosis in tissue samples is usually done by counting of apoptotic versus non-apoptotic 
cells. Western blot analysis of cell lysates with antibodies specific for phosphorylated 
caspase 3 can reveal the activity of apoptosis related signaling cascades. In a DNA ladder 
assay isolated DNA is cut enzymatically and analyzed on an agarose gel after staining with 
ethidium bromide. DNA fragments characteristic for apoptotic cells can be quantified. 
Isolated cells and cell lines in this work were analyzed either by analysis of nucleus 
fragmentation (“subG1-peak”) or an Annexin-V test: due to fragmentation of the DNA and the 
nucleus, propidium iodide stained apoptotic cells show DNA content lower than in haploid 
cells and so can be separated in a FACS histogram. Annexin-V binds to phospatidylserine 
which is translocated to the outer cell membrane of apoptotic cells. Double staining of cells 
with Annexin-V and propidium iodide and subsequent flow cytometric analysis can 
discriminate viable, necrotic and apoptotic cells. These two methods were performed with 
standardized routine protocols and yield highly reproducible results at high sample 
throughput. 
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3.1.3 The IAP Survivin is highly expressed in neoplastic mast cells 
Survivin plays an important role in the proliferation and maturation of normal hematopoietic 
cells (Fukuda, Foster et al. 2002; Fukuda, Mantel et al. 2004; Leung, Xu et al. 2007). 
Furthermore its expression in cells of this lineage seems to be linked to the expression and 
activity of the receptor tyrosine kinase c-KIT (Fukuda, Mantel et al. 2004; Jalal Hosseinimehr, 
Inanami et al. 2004; Fukuda, Singh et al. 2009).  
Analysis of bone marrow-derived mast cells, skin mast cells and the stem cell factor 
dependent mast cell line LAD-2, revealed low Survivin mRNA expression compared to  
HMC-1 cells carrying an activating c-KIT mutation. The same pattern was found for Survivin 
protein expression in CBMCs and LAD-2 cells when compared to HMC-1 cells. Survivin 
specific staining of bone marrow from patients with mastocytosis and donors with reactive 
bone marrow infiltrates showed high expression of Survivin protein in the mastocytosis group 
while no Survivin was expressed in samples of the control group. The finding of higher 
Survivin expression during the comparison of IAP expression in both HMC-1 clones gives 
another hint on the connection between c-KIT activation and Survivin expression in mast 
cells. Although a strong link between Survivin expression and severity of common human 
neoplasms exists (Altieri 2003; Kanwar, Kamalapuram et al. 2010) no direct correlation 
between Survivin expression in mast cells of mastocytosis patients, severity of disease and 
other factors tested like serum tryptase level could be observed at a statistical significant 
level. Due to the small number of patients included in this study and the semi-quantitative 
analysis of histological data further studies with higher number of patients will be necessary 
possibly including other disease-relevant factors and the use of quantitative methods of 
analysis. 
Since elevated expression of Survivin seems to be a feature of neoplastic transformed mast 
cells and bone marrow sections are still required for establishing a pathological diagnosis, 
staining for Survivin could be an additional tool to solidify diagnosis, and in case of further 
studies linking different c-KIT mutations with levels of Survivin expression, a prognostic 
marker. The downregulation of Survivin in neoplastic HMC-1.2 mast cells presented in this 
work shows the possible value of an anti-Survivin therapy in combination with approved 
therapies of mastocytosis like the use of tyrosine kinase inhibitors or possible new 
approaches like the activation of the apoptosis inducing TRAIL receptors. 
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3.1.4 TRAIL receptors in HMC-1 cells are differently expressed and 
murine bone marrow-derived mast cells TRAIL-R expression 
and function is influenced by c-KIT activity 
As has been previously shown (Berent-Maoz, Piliponsky et al. 2006) TRAIL-R1 and TRAIL-
R2 are expressed on human lung-derived mast cells, cord blood-derived mast cells and 
HMC-1.2 cells. In contrast to Fas mediated apoptosis all tested mast cells were sensitive to 
TRAIL-FLAG. TRAIL-R1 and TRAIL-R2 expression was compared in CBMC of different 
donors showing pronounced surface expression of TRAIL-R2 protein.  
The results presented here show a pronounced surface expression of TRAIL-R1 protein on 
both HMC-1 subclones and activation of TRAIL-R1 alone was sufficient to induce apoptosis 
in both cell lines (data not shown). Still this work confirmed the overall moderate sensitivity of 
HMC-1 cells towards TRAIL induced apoptosis compared to those of highly sensitive cells 
like JURKAT T cells. Several studies have linked the predominant TRAIL-R1 expression to 
more aggressive state of disease like in breast cancer (McCarthy, Sznol et al. 2005) and 
colon cancer (van Geelen, Westra et al. 2006). Further studies will be made to analyze 
TRAIL-R expression on mast cells from mastocytosis patients and healthy donors to check 
for a possible connection between differential TRAIL-R expression and disease state. 
IgE-dependent activation increases human cord blood-derived mast cells sensitivity towards 
TRAIL-induced apoptosis (Berent-Maoz, Salemi et al. 2008). IgE increased the expression of 
the anti-apoptotic molecules FLIP and MCL-1 and the pro-apoptotic molecule BIM. TRAIL 
reversed the increase of FLIP expression and induced apoptosis.  
BMMC were used to show functional TRAIL-R expression on murine mast cells and to study 
its regulation on primary cells with regards to future experiments with a recently generated 
mouse model of mastocytosis (Gerbaulet, Wickenhauser et al. 2010). To analyze the effect 
of stem cell factor on TRAIL-R expression the murine system was chosen since primary 
murine mast cells are viable and can be cultivated in SCF free medium while human mast 
cells instantly undergo apoptosis under SCF deprivation. Here the analysis of mouse derived 
BMMC revealed a dose dependent upregulation of TRAIL-R upon activation with SCF 
comparable with the upregulation following IgE-dependent activation. Quantitative PCR 
analysis showed no increase in FLIP mRNA nor did Western blot analysis show increased 
FLIP protein expression upon SCF activation while protein expression of MCL-1 was 
increased (data not shown). Combination of IgE-dependent activation and stimulation with 
SCF did not result in an additive effect. By which signaling pathway SCF is regulating  
TRAIL-R expression still has to be investigated. Further incubation of BMMC with SCF 
increased their sensitivity towards TRAIL-induced loss of viability and increase of apoptosis. 
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As a control TRAIL-R-/- BMMC were analyzed. These were generated by crossing TRAIL-R-
floxed mice with Deleter-cre mice. Isolated BMMC did not contain TRAIL-R DNA as was 
shown by specific PCR and showed no expression of TRAIL-R protein as was analyzed by 
flow cytometry. Incubation with TRAIL alone or TRAIL and SCF did not change their rate of 
viability nor resulted in apoptosis. Additionally our group is analyzing mice specifically lacking 
TRAIL-R on mast cells generated by crossing TRAIL-R floxed mice to mice expressing mast 
cell specific cre recombinase (Scholten, Hartmann et al. 2008). To date no differences in 
mast cell numbers, differential mediator release from mast cells or sensitivity towards 
anaphylaxis has been shown. 
These results are in contrast to data published for erythroid progenitors which show reduced 
sensitivity towards TRAIL induced apoptosis following stimulation with SCF (Schmidt, van 
den Akker et al. 2004). 
This data indicates a biological function of the TRAIL-R on BMMC since its expression is 
linked to SCF, the most important mast cell cytokine responsible for mast cell functions like 
proliferation, migration and cytokine release. Since the TRAIL concentrations used to induce 
apoptosis are very high, other functions of TRAIL i.e. in combination with SCF or IgE-
dependent activation will be subject of future investigation by analyzing mice lacking    
TRAIL-R on mast cells. 
 
3.1.5 Downregulation of Survivin increases neoplastic human mast 
cells sensitivity towards TRAIL and tyrosine kinase inhibitors 
Targeting the small inhibitor of apoptosis protein Survivin in neoplastic disorders seems to be 
a most promising approach since this molecule is not only sharply differentially expressed in 
disease (Altieri 2006) but has the role of a nodal protein being involved in multiple signaling 
mechanisms controlling cell division, modulation of apoptotic and non-apoptotic cell death, 
stress response and cell survival (Altieri 2006; Lens, Vader et al. 2006). A global 
deregulation of the survivin gene mediated by oncogenes, including STAT3 (Kanda, Seno et 
al. 2004) and the phosphatidylinositol 3-kinase – Akt axis (Asanuma, Torigoe et al. 2005) 
accounts for the selective expression of Survivin. Since all mutant c-KIT receptors 
investigated to date signal via the STAT3 (Chaix, Lopez et al. 2010) and STAT5 – PI3K – Akt 
(Harir, Boudot et al. 2008) pathway this could explain the high expression of survivin in 
mastocytosis. Compared to other myeloid cells such as basophiles, mast cells are extremely 
long-lived but factors responsible for their long term survival are largely unknown. 
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The data provided here shows that Survivin is a critical survival molecule in neoplastic mast 
cells. The downregulation of Survivin in HMC-1 cells leads to decreased survival and 
increased sensitivity towards tyrosine kinase inhibitors or TRAIL-induced apoptosis. Survivin 
is a chromosomal passenger protein (Adams, Carmena et al. 2001) and the decreased 
proliferation of HMC-1 cells after Survivin-specific siRNA plasmid transfection is most likely 
due to inhibition of the cell cycle as own preliminary data and others (Lens, Wolthuis et al. 
2003) have shown. Survivin has a complex role in the inhibition of apoptosis connecting to 
multiple parallel pathways that regulate gene expression, protein-protein interactions and 
mitochondrial functions. Survivin exhibits parallel interactions with other members of the IAP 
gene family. It binds to XIAP resulting in increased XIAP stability against proteasomal 
degradation and inhibition of apoptosis by synergistical inhibition of caspase 3 and 9 (Dohi, 
Beltrami et al. 2004) and a Survivin-cIAP1 complex might antagonize the  function of survivin 
in late-stage cell division (Samuel, Okada et al. 2005). In mitochondria Survivin binds Smac 
and so preventing it from binding to XIAP which is subsequently hindered to inhibit caspases 
(Sun, Nettesheim et al. 2005). Taken together these effects of Survivin seem to be sufficient 
to explain the combined effect of Survivin downregulation with enhanced intrinsic apoptosis 
induced by tyrosine kinase inhibitors and the increased sensitivity to extrinsic apoptosis 
initiated by TRAIL.   
 
3.1.6 LCL161 does sensitize neoplastic human mast cells to TRAIL 
and PKC412 
In a second approach the small molecule Smac mimetic LCL161 was used to target multiple 
IAPs, namely XIAP, cIAP1 and cIAP2, while initiating apoptosis by the tyrosine kinase 
inhibitor PKC412 and the death receptor ligand TRAIL. LCL161 (Weisberg, Ray et al. 2010) 
is a structural analog of the previously developed Smac mimetic LBW242 (Weisberg, Kung et 
al. 2007) a 3mer based on the NH2-terminal seven amino acids of Smac designed to 
neutralize the BIR3 domain of XIAP and to enhance the activity of different pro-apoptotic 
pathways (Galban, Hwang et al. 2009).  
The combined treatment of Smac mimetics resembling the N-terminal residues of Smac 
together with TRAIL has been shown to potentiate the apoptotic effect on JURKAT cells 
compared to treatment with TRAIL alone (Guo, Nimmanapalli et al. 2002). This increase in 
apoptosis was accompanied by downregulation of XIAP, cIAP1, cIAP2 and Survivin and 
commensurate activation of caspase 3 and 8. Enhanced TRAIL induced apoptosis after 
small molecule Smac mimetic treatment has been shown for example in glioblastoma cells 
(Li, Thomas et al. 2004), breast cancer cells (Bockbrader, Tan et al. 2005) and ovarian 
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cancer cells (Petrucci, Pasquini et al. 2007). LBW242 acted in positive synergy with TRAIL to 
induce apoptosis in multiple myeloma cells (Weisberg, Kung et al. 2007) and LCL161 
synergistically inhibited cellular proliferation of murine leukemic pro-B cells in vitro and in vivo 
with PKC412 (Weisberg, Ray et al. 2010). 
Incubation with LCL161 alone resulted in reduced proliferation demonstrated by cell cycle 
analysis showing accumulation of HMC-1 cells in the G1 phase as wells as increased 
apoptosis of the cells as shown by Annexin-V staining. Co-incubation with PKC412 and 
TRAIL increased the rate of apoptosis in a synergistical manner. This result could be an 
indication that the combined treatment of neoplastic mast cell diseases with Smac mimetics 
showing a low toxicity profile in normal hematopoietic progenitors (Servida, Lecis et al. 2010) 
and tyrosine kinase inhibitors or TRAIL could be a future treatment option.  
 
3.1.7 Conclusion and Outlook 
Interference with components of the cellular apoptosis pathways could be a beneficial way of 
enhancing therapy of mastocytosis. Mast cells generation time and survival rate within 
tissues is mainly controlled by the presence of stem cell factor. In absence of SCF mast cells 
undergo apoptosis (Iemura, Tsai et al. 1994). Current therapy of mastocytosis uses tyrosine 
kinase inhibitors to interfere with the survival signaling of the KIT receptor. Human mast cells 
express functional TRAIL receptors and their neoplastic transformation in mastocytosis 
renders them even more vulnerable towards TRAIL induced apoptosis (Berent-Maoz, 
Piliponsky et al. 2006). Downregulation or inhibition of anti-apoptotic molecules in neoplastic 
mast cells is a favorable way of enhancing induction of apoptosis either by intrinsic apoptotic 
stimuli like inhibition of KIT signaling by TK inhibitors or by targeting the extrinsic apoptotic 
pathway with TRAIL. The IAP Survivin is highly expressed in neoplastic mast cells compared 
to normal mast cells thus making it an excellent diagnostic marker in mastocytosis. Moreover 
its downregulation resulted in inhibition of mast cell proliferation and acted synergistically 
with TK inhibitors and TRAIL in reducing their viability. The promising effect of Smac 
mimetics as new cancer drugs was also seen in neoplastic mast cells. LCL161 inhibited 
growth of HMC-1 cells and amplified the reduction of viability and the apoptosis induced by 
PKC412 and TRAIL showing that targeting XIAP, cIAP1 and cIAP2 in mastocytosis is a 
beneficial option. Recently the link between both approaches becomes more obvious. Not 
only has been shown that Survivin and Smac/DIABLO form a complex promoting apoptosis 
(Song, Yao et al. 2003) but also Survivin and XIAP form a complex in which XIAP is 
stabilized by Survivin, protected from proteasome-mediated degradation and synergistically 
induces apoptosis (Dohi, Okada et al. 2004; Hu, Liu et al. 2010) and also participates in 
tumor cell invasion and metastasis (Mehrotra, Languino et al. 2010). These finding will direct 
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attention to investigation of combined inhibitors for Survivin and Smac/DIABLO (Oikawa, 
Unno et al. 2010) as well as Survivin and XIAP (Obiol-Pardo, Granadino-Roldan et al. 2008) 
allowing more efficient treatment of neoplastic malignancies like mastocytosis where 
combined approaches with induced apoptosis and simultaneous reduction of apoptosis 
inhibition can open new therapeutic perspectives. 
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4 Materials and Methods 
 
4.1 Chemicals and enzymes 
Unless otherwise specified, all standard chemicals were purchased from Roth (Karlsruhe), 
Merck Biosciences (Darmstadt), Serva (Heidelberg) or Sigma-Aldrich (München). 
 
4.2 Mice 
 
4.2.1 Mouse strains 
All mice were on the C57BL/6 background and crossed exclusively to C57BL/6 mice. 
Following mouse lines were used in this thesis: Mice conditionally deficient for the TRAIL-r 
gene loxP sites flanking exon 2 so that upon expression of the Cre recombinase, a frame 
shift and an early stop codon is introduced resulting in a transcript devoid of TRAIL-binding 
cysteine-rich domains and an apoptosis-inducing death domain (Grosse-Wilde, 
Voloshanenko et al. 2008). Cre deleter mice, a cre-transgenic mouse strain for the ubiquitous 
deletion of loxP-flanked gene segments including deletion in germ cells (Schwenk, Baron et 
al. 1995). Mice were kept under specific pathogen free (SPF) conditions and all experiments 
were done according to institutional guidelines. 
 
4.3 Cells and cell culture 
 
4.3.1 Cell culture media and reagents 
Penicillin/Streptomycin: 100 U/ml penicillin, 0.1 mg/ml streptomycin (final concentrations, 
Biochrom AG, Berlin) 
L-glutamine: 2 mM final concentration (Biochrom AG, Berlin) 
DMEM (Invitrogen, Darmstadt): supplemented with 10% FCS (Biochrom AG, Berlin), 50 µM 
β-mercaptoethanol (Sigma-Aldrich, München), L-glutamine, penicillin/streptomycin. 
IMDM (Invitrogen, Darmstadt): supplemented with 10% FCS (Biochrom AG, Berlin), 1.2 mM 
α-thioglycerol (Sigma-Aldrich, München), L-glutamine, penicillin/streptomycin. 
1 x PBS: 10 mM Na2HPO4, 1.5 mM KH2PO4, 2.6 mM KCl, 136 mM NaCl, pH 7.4 
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RPMI-1640 (Invitrogen, Darmstadt): supplemented with 10% FCS (Biochrom AG, Berlin), L-
glutamine, penicillin/streptomycin. 
StemPro-34 (Invitrogen, Darmstadt) 
WEHI-3B conditioned medium: Supernatant of IL-3 producing WEHI-3B cells purchased 
from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig). 
The medium was prepared by culturing 1x105 WEHI-3B cells in complete IMDM containing 
10% FBS, 25 µM β-mercaptoethanol (Sigma-Aldrich, München), L-glutamine and 
penicillin/streptomycin for 3-4 days until cell density reached about 1x106 cells/ml. Cells were 
carefully mobilized from the culture dish bottom using a cell scraper, centrifuged and the 
supernatant was collected. 50 ml aliquots were stored at -20 °C. 
 
4.3.2 HMC-1 
The HMC-1 cell lines have been established in 1988 by Butterfield et al. from peripheral 
blood from patients with mast cell leukemia (Butterfield, Weiler et al. 1988). The ultra 
structure of the cultivated cells shows characteristics of immature mast cells (Nilsson, Blom 
et al. 1994). HMC-1 cells can be stained by toluidine-blue. Like in mature mast cells 
histamine, tryptase, heparin and chondroitin sulfate can be detected within the cells. In 
contrast to primary human mast cells, no surface expression of the Fcε-receptor is 
detectable. HMC-1.1 cells carry one mutation at codon 560 in the juxtamembrane region of 
the c-KIT gene causing a substitution of Gly-560 for Val. In contrast only HMC-1.2 cells carry 
the mutation at codon 560 and a mutation at codon 816 causing an AspVal substitution in 
the intracellular kinase domain. Both mutations lead to KIT phosphorylation on tyrosine 
residues and are associated with phosphatidylinositol 3’-kinase (PI 3-kinase) activation but 
no constitutive activation of Akt or extracellular regulated protein kinase (ERK), which are 
signaling molecules normally activated by the interaction of stem cell factor (SCF) with KIT 
(Furitsu, Tsujimura et al. 1993; Kanakura, Furitsu et al. 1994; Weber, Babina et al. 1996; 
Sundstrom, Vliagoftis et al. 2003). HMC-1 cell can spontaneously release IL-1α, IL-1β, IL-6, 
IL-8 and TNF-α, while secretion of IL-2, IL-3, IL-4 and IL-7 has not been shown (Grabbe, 
1994). HMC-1 cells were cultivated in Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin, 50 
µg/ml streptomycin, 1.2 mM α-thioglycerol in a humidified incubator (at 37°C, 5% CO2) and 
were passaged every 3-4 days. 
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4.3.3 KU812 
The cell line KU812 has been isolated in 1985 from a patient with chronic myeloid leukemia 
during a blast crisis. It is Philadelphia chromosome positive and shares characteristics with 
basophiles (i.e. expression of the IL-3 receptor) and mast cells (i.e. tryptase expression) 
(Kishi 1985). In contrast to HMC-1 cells KU812 do not carry KIT mutations and they express 
the FcεR (Hamann, Grabbe et al. 1994). Cells were cultivated in RPMI-1640 medium 
supplemented with 10% calf serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin under the 
same conditions as the HMC-1 cells. 
 
4.3.4 C57.1 
The C57.1 murine mast cell line has been isolated in 1987 from bone marrow of a C57BL/6J 
mouse. The cells grow IL-3 independent, contain histamine and express the FcεR (Young, 
Liu et al. 1987). C57.1 cells were cultivated in Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin, 50 
µg/ml streptomycin, 1.2 mM α-thioglycerol under the same conditions as the HMC-1 cells. 
 
4.3.5 Cord Blood Derived Mast Cells (CBMC) 
The cultivation of immature mast cells from human cord blood is an established model for the 
generation of primary human mast cells (Dvorak, Furitsu et al. 1992; Mitsui, Furitsu et al. 
1993). These cells were generated from umbilical cord blood mononuclear cells cultured in 
medium containing SCF. After eight weeks of culture of mononuclear cells from one umbilical 
cord, cultures of more than 90% mast cells can be generated, determined by flow cytometric 
detection of FcεR and KIT. The KIT expressing cells stain tryptase and partially chymase 
positive. As studies have shown CBMC do not carry mast cell typical crystal-granules and 
their histamine release pattern differs from primary human mast cells (Amano, Kurosawa et 
al. 2000; Matsushima, Ishikawa et al. 2000). Heparinized cord blood was mixed 1:1 with 
Hank’s Balanced Salt Solution (HBBS). 20 ml were loaded on 12 ml Ficoll in a falcon tube 
and centrifuged for 20 min at 2000 rpm. Mononuclear cells were extracted, washed twice 
with HBBS and cultured in RPMI 1640 medium containing 20% fetal calf serum (FCS), 2 mM 
L-glutamine, 100 IU/ml penicillin/streptomycin and 100 ng/ml SCF. Cells were incubated in a 
humidified incubator (at 37°C, 5% CO2) for 8 to 16 weeks with a weekly change of medium 
and maturation was determined by flow cytometric analysis of KIT (CD117) and tryptase. 
 
Materials and Methods 50 
4.3.6 Bone Marrow- Derived Mast Cells (BMMC) 
Immature murine mast cells can be grown from murine bone marrow cultured in IL-3 
containing medium (Yung, Eger et al. 1981). Bone marrow from femurs of 4-8 week-old mice 
was placed in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal calf serum 
(FCS), 2 mM L-glutamine, 100 IU/ml penicillin/streptomycin and 20% conditioned medium 
from WEHI-3 cells containing IL-3. BMMC were enriched by discarding adherent cells. The 
isolated BMMC were maintained in culture at 0.5-1.0 x 106 cells/ml for 4-6 weeks. Before 
use, BMMC purity was routinely monitored by flow cytometry to detect KIT and FcεRI. 
 
4.3.7 Skin Mast Cells 
Skin mast cells were isolated from human foreskin and purified by sorting using the 
monoclonal anti-c-KIT antibody YB5B8 and a secondary magnetic microbead-coupled 
antibody as previously detailed described (Grutzkau, Henz et al. 2000). 
 
4.3.8 JURKAT cells 
The JURKAT human T cell line was established from a patient with acute lymphocytic T cell 
leukemia (Schneider, Schwenk et al. 1977). The cell line was grown in suspension in in 
RPMI 1640 medium supplemented with 2 x 10-3 M L-glutamine, penicillin (10 U/ml), 
streptomycin (0.1 mg/ml) and 10% heat-inactivated fetal calf serum (FCS). The cells were 
maintained in a 37°C, 5% CO2 incubator in sealed flasks and were subcultured every 2 days. 
 
4.3.9 LAD-2 cells 
The LAD-2 cell represents a recently established MC sarcoma cell line (Kirshenbaum, Akin 
et al. 2003). The cells closely resemble primary cultures of CD34+-derived human mast cells, 
respond to rhSCF and have functional FcεRI and FcγRI receptors. LAD-2 cells survive in 
culture without SCF, and double in numbers in approximately 3 weeks in the presence of 100 
ng/ml SCF. The slower doubling time reflecting cell proliferation and death, in contrast to 3-5 
days for some tumorigenic cell cultures, may allow LAD-2 cells to exhibit a more mature 
phenotype. Cells were routinely cultured in StemPro-34 in the presence of 100 ng/ml rhSCF. 
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4.4  Stimulation of cells 
 
4.4.1 Materials 
Enhance for Ligands (Axxora, San Diego, CA): Stock solution: 1 mg/ml 
LCL161 (Novartis, Basel): Stock solution 10 nM 
Nilotinib (AMN107) (Novartis, Basel): Stock solution 10 nM 
PKC412 (Midostaurin) (Novartis, Basel): Stock solution 10 nM 
Flag-tagged recombinant human TRAIL (Axxora, San Diego, CA): Stock solution: 100 
µg/ml 
 
4.4.2 Methods 
For siRNA transfection, 2 x 106 HMC-1 cells in exponential growths were suspended in 100 
µl Nucleofector solution V and transfected with 3 µg of pSuper-Luc or 3 µg of pSuper-
Survivin using a Nucleofector I, program T-030 (Amaxa Biosystems), following the 
manufacturer’s instructions. After transfection cells were resuspended in medium containing 
tyrosine kinase inhibitors Nilotinib (10 µM) or PKC412 (500 nM), recombinant human TRAIL 
(250 ng/ml) and Enhancer for Ligands (2 µg/ml) or medium alone. Cells were incubated for 
24 to 72 hours before measurement of apoptosis. 
For LCL161 studies 5 x 105 HMC-1 cells were suspended in 1 ml medium containing 
indicated concentrations of LCL161, tyrosine kinase inhibitors, recombinant human TRAIL 
and 2 µg/ml Enhancer for Ligands for up to 72 h before further analysis. 
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4.5 Analysis of cells 
 
4.5.1 Materials 
Annexin-V - APC (eBiosciences, San Diego, CA): 20 x Stock solution 
10 x Annexin-V Binding Buffer (eBiosciences, San Diego, CA): diluted 1 + 9 with ddH2O 
FACS buffer: 1 x PBS, 0,5% (w/v) BSA (Serva, Heidelberg), 2mM EDTA in ddH2O 
Lysis buffer for Western blot: 50 mM Tris-Cl pH 7.4, 1% NP-40 (Pierce, Rockford, USA), 
sodium deoxycholate 0.25%, 150 mM NaCl, 1 x Complete protease inhibitor cocktail (Roche; 
Mannheim), 1 x PhosSTOP phosphatase inhibitor cocktail (Roche; Mannheim) 
Human Fc Receptor Binding Inhibitor (eBiosciences, San Diego, CA): 5 x stock solution 
PBS 1x: 10 mM Na2HPO4, 1.5 mM KH2PO4, 2.6 mM NaCl (all Sigma-Aldrich, München), pH 
7.4 
Propidium iodide (Sigma-Aldrich, München): 1 mg/ml Stock solution in ddH2O, working 
dilution 1:100, final concentration 0.5 µg/ml 
RNase A (Qiagen, Hilden): 100 mg/ml Stock solution 
RNA-Safe-Buffer: 0.05% Tween 20 (Roche, Mannheim), 0.05% sodium azide (Sigma-
Aldrich, München) 
Sample buffer for Western blot: 250 mM Tris-Cl pH 6.8, 20% glycerol, 2% (w/v) Sodium 
Dodecyl Sulfate, 5% β-mercaptoethanol, 0.5‰ bromphenol blue,  
TAE 1 x: 40 nM Tris-Cl, 20 nM NaAc, 1 mM EDTA (all Sigma-Aldrich, München) 
TBS-T: 25 nM Tris-Cl, 150 nM NaCl, 0.1% (v/v) Tween 20 (Serva, Heidelberg), pH 7.6 
 
4.5.2 Reverse Transcription – PCR 
RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden) and was stored at -80 °C in 
RNA-Safe-Buffer and concentration was determined by measuring absorbance in a 
spectrophotometer at 260 nm. Polyadenylated RNA was transcribed with the Superscript III 
First Strand Synthesis Kit (Invitrogen, Darmstadt) using oligo-dT primers following 
manufacturer’s instructions. Synthesized cDNA was used as PCR template after RNAse H 
(Roche, Mannheim) digestion. 
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100 ng DNA was added to 50 µl 1 x reaction buffer (Fermentas, St. Leon-Roth) with 200 nM 
of each primer (Metabion, Martinsried), 200 µM dNTP Mix, 1.5 mM MgCl2 and 0,025 U/µl Taq 
DNA polymerase (all Fermentas, St. Leon-Roth). In a first step the reaction mixture is heatet 
at 95 °C for 2 min for denaturation of the template followed by 30-40 repeats of following 
steps:  
1. Denaturation: 95 °C for 30 s 
2. Annealing of primers at specific temperature tA for 45 s 
3. Elongation of products at 72 °C for 1 min/kb. 
A final elongation step of 72 °C for 7 min is performed for each protocol. 
The PCR products were separated by electrophoresis on a 1-2% (m/v) gel composed of 
agarose (BioBudget, Krefeld) in 1 x TAE buffer, stained with 30 ng/ml ethidium bromide 
(Merck, Darmstadt) and visualized under UV light. Predicted product size was checked with 
the GeneRuler™ DNA Ladder Mix (Fermentas, St. Leon-Roth). 
 
4.5.2.1 Isolation of genomic tail DNA 
Mouse tail tips, about 0.5 cm in length, were incubated overnight at 55 °C rocking in 500 µl 
lysis buffer (200 nM TrisCl, 100mM NaCl, 1% SDS (w/v), 50 mM EDTA) supplemented with 
100 µg Proteinase K (Fermentas Life Sciences). Undigested material was sedimented by 
centrifugation and the supernatant was poured into a fresh 1.5 ml microcentrifuge tube 
containing 500 µl isopropanol. The samples were mixed by inverting the tubes several times. 
The precipitated DNA was pelleted by centrifugation by centrifugation and washed once with 
70% ethanol. The air dried pellet was dissolved in TE buffer by incubating at 55 °C shaking 
for at least 2 h. 
 
4.5.2.2 Genotyping protocols 
Mice were genotyped by using the standard PCR program (see section 4.5.2) with varying 
annealing temperatures (TA) and cycle numbers. Primers for genotyping are listed in table 
4.1. 
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4.5.3 Immunohistochemistry 
For analysis of mastocytosis lesions in bone marrow specimens were fixed in formalin over 
night and embedded in paraffin. 6 µm sections were first stained with anti-tryptase antibody 
(DAKO, Glostrup, Denmark) and costaining of mast cell infiltrates with an antibody against 
survivin (R&D Systems, Wiesbaden) was then assessed in serial sections. Before exposure 
to antibodies, antigen unmasking was performed by incubation the bone marrow sections in 
10 mM Na-citrate buffer pH 6 at 95 °C. Detection followed by secondary antibody staining 
and use of the Vectastain Elite ABC Kit. 
4.5.4 Western blot analysis 
2 x 105 cells per sample were harvested and lysed in 20 µl lysis buffer on ice for 30 minutes. 
20 µl of sample buffer was added and sample was denaturized at 95 °C for 5 minutes. 
Samples were separated on a 10 – 15% SDS-gel and electroblotted on a nitrocellulose 
membrane (Amersham, GE Healthcare, München). 
Membranes were blocked one hour with TBS-T containing 10% milk powder and 0.1 % BSA. 
Primary antibodies were diluted in either TBS-T + 5% (m/v) milk powder or TBS-T + 5% (m/v) 
BSA and incubated either 1h at room temperature or over night at 4 °C according to the 
manufacturer’s instructions. Secondary antibodies swine-anti-rabbit-peroxidase, rabbit-anti-
mouse-peroxidase and rabbit-anti-goat-peroxidase (all DAKO, Glostrup, Denmark) were 
diluted in TBS-T + 5% (m/v) milk powder according to manufacturer’s instructions and 
incubated at room temperature for one hour. The blocking step and each antibody incubation 
were followed by 30 minutes of washing with TBS-T at room temperature.Signals were 
detected with ECL reagent on Hyperfilm ECL both GE Amersham. 
 
4.5.5 Flow cytometry 
For antigen staining 1 x 105 cells were harvested and washed twice with FACS buffer. Cells 
were resuspended in human Fc Receptor Binding Inhibitor and were stored on ice for 20 
minutes. Hereafter cells again were washed twice with cold FACS buffer and incubated with 
an appropriate antibody dilution (see table 4.3) in FACS buffer and incubated on ice for 30 
minutes in the dark. After washing the cells again twice with FACS buffer they were stored on 
ice resuspended in 200 µl FACS buffer until flow cytometric analysis. 
For apoptosis detection 1 x 105 cells were harvested and washed once with PBS and once 
with Annexin-V Binding Buffer. Cells were resuspended in 100 µl Binding Buffer and 5 µl 
Annexin-V-APC was added. Cells were incubated for 15 minutes at room temperature in the 
dark. After cells were washed again in Binding Buffer they where resuspended in 200 µl 
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Binding Buffer and propidium iodide (final concentration 0.5 µg/ml) was added 5 minutes 
before cell analysis. 
For cell cycle analysis 1 x 106 cells were fixed with 70% ethanol (-20 °C) and resuspended in 
PBS. RNA was digested with RNase A (50 µg/ml) at 37 °C for 30 minutes in the dark. Cells 
where stained with propidium iodide (final concentration = 50 µg/ml) five minutes before flow 
cytometric analysis. 
Cells were analyzed with a FACS Calibur (BectonDickinson, Heidelberg) with a 488 and 633 
nm laser. Data was acquired and analyzed with CellQuest Pro Software Version 5.2.1.  
 
4.5.6 Cell proliferation 
Cell proliferation was measured with the CellTiter 96® AQueous One Proliferation Assay 
(Promega, Mannheim).  
Briefly, quadruplicates of 2 x 104 cells per condition were seeded in 100 µl of culture medium 
in wells of a 96 well plate. 20 µl of CellTiter 96® AQueous Solution Reagent was added to each 
well and the plate was incubated at 37 °C in a humidified incubator with 5% CO2 for 1 h. 
Absorbance at 490 nm was measured in a 96 well plate reader. 
 
4.6 Oligonucleotides 
All oligonucleotides were produced by Metabion (Martinsried) and purified by HPLC. 
Name  Sequence (5’-3’)   PCR product  TA and  
cycle number 
 
Deleter Fwd GAAAGTCGAGTAGGCGTGTACG 600 bp   58 °C, 35 cycles 
Deleter Rev CGCATAACCAGTGAAACAGCAT 
GAPDH fw ATGGGGAAGGTGAAGGTCG  226 bp   62 °C, 30 cycles 
GAPDH rev GGGGTCATTGATGGCAACAATA 
mTRAIL-R fw CGGGCAGATCACTACACCC  147 bp   63°C, 30 cycles 
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Name  Sequence (5’-3’)   PCR product  TA and  
cycle number 
mTRAIL-R rev TGTTACTGGAACAAAGACAGCC 
mTRAIL fw ATGGTGATTTGCATAGTGCTCC 193 bp   62°C, 30 cycles 
mTRAIL rev GCAAGCAGGGTCTGTTCAAGA 
Survivin fw GTTTCCAGCGAAGCTGTAACA 473 bp   65 °C, 40 cycles 
Survivin rev GGTCCCCGCTTTCTTTGGAG 
TRAIL-R1 fw CCGCGGCCACACCCAGAAAGT 415 bp   61 °C, 30 cycles 
TRAIL-R1 rev GTACATGGGAGGCAAGCAAACAAA 
TRAIL-R2 fw GCGCCCACAAAATACACCGACGAT 437 bp   61 °C, 30 cycles 
TRAIL-R2 rev GCAGCGCAAGCAGAAAAGGAG 
TRAIL-R flox: 
P813  GAGCCATCTTTTTAAGTCTTGACT 300 bp = wt  59 °C, 35 cycles 
P814  GACGATTATGGGCTGGGTTAGCTG 470 bp = flox 
TRAIL-R knockout 
P813  GAGCCATCTTTTTAAGTCTTGACT 235 bp = knockout  59 °C, 35 cycles 
P815  CGAACACAGCTGGTTTCCATGG 800 bp = wt 
Table 4.1 Primers used for PCR analysis:  
fw = forward primer (3’-5’), rev = reverse primer (3’-5’) 
 
 
4.6.1 Plasmid based siRNA 
pSuper-Luc: pSuper-Luc coding for siRNA complementary to a target sequence in the 
luciferase gene of the american firefly (Photinus phyralis) here used as a control siRNA 
(Butz, Ristriani et al. 2003). 
pSuper-Survivin: pSuper-Survivin coding for siRNA complementary to a target sequence in 
the human survivin gene (Lens, Wolthuis et al. 2003). 
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4.7 Antibodies for Immunohistochemistry 
Antigen    Clone   Dilution Manufacturer 
Survivin    Rabbit, polyclonal  IgG 1:40  R&D Systems 
Tryptase    AA1     1:50  Dako 
Table 4.4 Antibodies for Immunohistochemistry: 
Dako, Glostrup, Denmark; R&D Systems, Wiesbaden. 
 
 
4.8 Antibodies for Western blot analysis 
Antigen    Host/Isotype  Dilution Manufacturer 
β-Actin     Mouse polyclonal 1:5000  Sigma-Aldrich 
c-IAP1     Rabbit polyclonal 1:1000  Cell Signaling 
c-IAP2     Rabbit IgG  1:1000  Cell Signaling 
cFLIP     Rabbit IgG  1:500  Abnova 
Mcl-1     Rabbit IgG  1:500  BioLegend 
Noxa     Mouse IgG1  1:1000  Abcam 
Phospho-Akt (Ser 473)   Rabbit polyclonal IgG 1:1000  Cell Signaling 
Phospho-ERK1/2 (Thr202/Tyr204) Mouse IgG1  1:1000  Cell Signaling 
Phospho-Stat5 (Tyr694)  Rabbit IgG  1:1000  Cell Signaling 
Smac/Diablo    Mouse IgG1  1:1000  Cell Signaling 
Survivin    Rabbit, polyclonal  IgG 1:400  R&D Systems 
TRAIL     Rabbit IgG  1:200  Novus Biologicals 
XIAP     Rabbit IgG  1:1000  Cell Signaling 
Table 4.2 Antibodies for Western blot analysis:  
Abnova, Heidelberg; Abcam, Cambridge; Cell Signaling, Danvers, MA; R&D Systems, Wiesbaden; 
Sigma-Aldrich, München.  
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4.9 Antibodies for flow cytometric analysis 
Antigen Host/Isotype Clone  Dilution Dye  Manufacturer 
CD117  Rat IgG2b,κ   1:500  APC  eBiosciences 
FcεRIα  Hamster IgG   1:300  Phycoerythrin eBiosciences 
Isotype  Mouse IgG1,κ   1:300  Phycoerythrin eBiosciences 
Isotype  Rat IgG2a,κ   1:300  Phycoerythrin eBiosciences 
mTRAIL-R Rat IgG2a,κ N2B2  1:300  Phycoerythrin eBiosciences 
TRAIL-R1 Mouse IgG1,κ DJR1  1:300  Phycoerythrin eBiosciences 
TRAIL-R2 Mouse IgG1,κ  DJR2-4  1:300  Phycoerythrin eBiosciences 
Table 4.3 Antibodies for flow cytometric analysis: 
eBiosciences, San Diego, CA. 
 
 
4.10 Statistical analysis 
To determine the level of significance in differences found in data evaluation, the paired 
Student t test was applied. Results were considered significantly different at P < .05. To 
determine synergistic effects of TRAIL-FLAG and drugs, combination index values were 
calculated based on the method of Chou et al. 1984 (Chou and Talalay 1984) and were 
calculated as a combination index (CI) with CI < 1, CI =1 or CI > 1 representing synergism, 
additivity or antagonism, respectively. 
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5 Abbreviations 
BMMC   bone marrow-derived mast cells 
bp   base pair 
BSA   bovine serum albumin 
CM   Cutaneous mastocytosis 
ddH2O   bidestilled water 
DMEM   Dulbecco’s modified Eagle medium 
DNA   desoxyribonucleic acid 
dNTP   desoxyribonucleoside triphosphate 
E.coli   Escherichia coli 
EDTA   ethylene diamine tetraacetate 
ELISA   enzyme-linked immunosorbent assay 
FACS   fluorescent activated cell sorting 
FBS   fetal bovine serum 
FCS   fetal calf serum 
FcεRI   high-affinity IgE receptor 
g   gravitational acceleration, 9.81 ms-1 
h   hours 
HPLC   High-performance liquid chromatography 
Ig   immunoglobulin 
IL   interleukin 
IMDM   Iscove’s Modified Dulbecco’s Media 
ISM   indolent systemic mastocytosis 
kb   kilobases 
l   liters 
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MACS   magnetic activated cell sorting 
MCL   mast cell leukemia 
mRNA   messenger ribonucleic acid 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PE   phycoerythrin 
PI   propidium iodide 
rpm   revolutions per minute 
RT   reverse transcription 
SCF   stem cell factor 
SDS   sodium dodecylsulfate 
SM   systemic mastocytosis 
SM-AHMND systemic mastocytosis with additional hematopoietic non-mast cell 
disease 
TA   annealing temperature 
TAE   Tris acetate EDTA buffer 
TE   Tris-EDTA 
TNFα   tumor necrosis factor α 
TRAIL   TNF-related apoptosis-inducing ligand 
Tris   Tris-(hydroxymethyl-)aminomethan 
U   unit 
v/v   volume per volume 
w/v   weight per volume 
wt   wild type 
WHO   World Health Organization 
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